MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025

FINANCIAL HIGHLIGHTS

	Year ended 31 December		
	2025	2024	Change
	US$'000	*US$'000*	*%*
Revenue	**1,105,381**	1,031,063	6.0% (excluding the foreign exchange impact)
Gross profit	**634,584**	574,092	10.5%
Non-GAAP operating profit/(loss) #	**330**	(123,218)	100.3%
Profit/(loss) for the year	**38,427**	(268,459)	114.3%
Profit/(loss) attributable to equity shareholders of the Company	**48,519**	(214,043)	122.7%
Profit/(loss) per share –			
Basic (in cents)	**2.59**	(11.68)	122.2%
Diluted (in cents)	**1.52**	(12.15)	112.5%
Net cash generated from/ (used in) operating activities	**69,132**	(49,669)	239.2%

Non-GAAP operating profit/(loss) is derived from gross profit less research and development costs, distribution costs and administrative expenses.

* *For identification purpose only*

A Key Financial Turning Point, Entering a New Phase Driven by Profitability. During the year ended 31 December 2025 (the "**Reporting Period**"), MicroPort Scientific Corporation (the "**Company**" or "**MicroPort®**") and its subsidiaries (collectively, the "**Group**") returned to profitability with a net profit of US$38.4 million. The Group's organic growth has entered a healthy trajectory and it has actively implemented strategic adjustments. During the Reporting Period, non-GAAP operating profit significantly increased by US$123.5 million and turned positive; and operating cash flow also turned positive to US$69.1 million, reflecting that the Group has entered a development cycle driven by profitability and healthy cash flow.

Strong Release of Global Momentum, with Platform Synergies Becoming Evident. During the Reporting Period, the Group's "GloMatrix" Commercialization Platform made positive progress, driving revenue growth of the related businesses by 78.8% year-on-year (excluding the foreign exchange impact) to US$163.9 million, and achieving breakeven during the Reporting Period. Specifically, overseas sales of core businesses such as surgical robots and structural heart disease expanded by 286.6% and 255.0% year-on-year, respectively (excluding the foreign exchange impact). The platform's revenue is becoming increasingly diversified, with business synergies continuously strengthening, steadily emerging as the core engine of the Group's growth.

Core Business Reinvented, Validating Business Model Resilience. As the Group's first core product line to undergo national centralized volume-based procurement, the cardiovascular intervention business has successfully navigated the industry cycle through its strategic transformation toward becoming a "total solution provider for coronary heart disease", maintaining a adjusted net profit margin of over 20% for two consecutive years, remaining steady and healthy, and fully validating its sustainable business model and operational resilience.

Closed-Loop Development of the Innovation Chain, Fueling Long-Term Growth. During the Reporting Period, the Group's innovation achievements systematically covered the entire chain spanning "frontier exploration – registration breakthroughs – product launch – high-level evidence generation". On the exploration and registration front, eight new products were added to the national innovative medical device green channel, bringing the total to 44, maintaining the top position in the industry for eleven consecutive years; and two products received "Breakthrough Device Designation" from the U.S. FDA. On the product and evidence front, several blockbuster products were approved and launched globally. Meanwhile, the full text of the clinical study on the self-developed Firehawk® coronary stent was published in The New England Journal of Medicine ("**NEJM**"), marking international top-tier academic recognition of the Group's R&D capabilities and laying a solid foundation for long-term development.

Strategic Restructuring Strengthens the Foundation, Ushering in a New Growth Curve. During the Reporting Period, the Group completed the strategic integration of its structural heart disease business and cardiac rhythm management business. This integration not only enhanced operational efficiency but also markedly improved the health of the financial statements of the Group. More strategically, through this integration, the Group has aggressively entered the high-value field of heart failure treatment, striving to build a global professional device platform covering the entire continuum of "monitoring – diagnosis – treatment – management" for heart failure. This initiative has opened up a promising new growth curve for the Group.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

for the year ended 31 December 2025
(Expressed in United States dollars)

	Note	2025 Continuing operations US$'000	2025 Discontinued operation (note 15(a)) US$'000	2025 Total US$'000	2024 Continuing operations US$'000	2024 Discontinued operation (note 15(a)) US$'000	2024 Total US$'000
Revenue	4	**994,909**	**110,472**	**1,105,381**	924,369	106,694	1,031,063
Cost of sales		**(441,398)**	**(29,399)**	**(470,797)**	(428,048)	(28,923)	(456,971)
Gross profit		**553,511**	**81,073**	**634,584**	496,321	77,771	574,092
Research and development costs		**(135,499)**	**(11,005)**	**(146,504)**	(202,958)	(13,557)	(216,515)
Distribution costs		**(294,601)**	**(23,514)**	**(318,115)**	(285,540)	(18,614)	(304,154)
Administrative expenses		**(160,804)**	**(8,831)**	**(169,635)**	(168,859)	(7,782)	(176,641)
Other net income	5	**47,647**	**7,348**	**54,995**	22,747	6,612	29,359
Other operating costs	6(b)	**(31,507)**	**(282)**	**(31,789)**	(13,135)	(125)	(13,260)
Finance costs	6(a)	**(111,261)**	**(222)**	**(111,483)**	(105,909)	(495)	(106,404)
Expected credit loss on trade and other receivables and financial guarantee issued		**(5,235)**	**–**	**(5,235)**	(2,250)	–	(2,250)
Changes in the fair value of convertible bonds		**(23,744)**	**–**	**(23,744)**	(18,849)	–	(18,849)
Changes in the fair value of other financial instruments		**(491)**	**(692)**	**(1,183)**	262	1,338	1,600
Impairment losses of non-current assets	6(c)	**(98,947)**	**(8,303)**	**(107,250)**	(87,864)	–	(87,864)
Gain on disposal of subsidiaries		**49,647**	**276,893**	**326,540**	98,155	–	98,155
Gain on disposal of interests in equity-accounted investees		**3,884**	**–**	**3,884**	16,729	–	16,729
Share of profits less losses of equity-accounted investees		**(25,090)**	**(3,552)**	**(28,642)**	(15,886)	(2,897)	(18,783)
Profit/(loss) before taxation	6	**(232,490)**	**308,913**	**76,423**	(267,036)	42,251	(224,785)
Income tax	7(a)	**(23,223)**	**(14,773)**	**(37,996)**	(36,104)	(7,570)	(43,674)
Profit/(loss) for the year		**(255,713)**	**294,140**	**38,427**	(303,140)	34,681	(268,459)

	Note	**2025 Continuing operations** ***US$'000***	**2025 Discontinued operation *(note 15(a))*** ***US$'000***	**2025 Total** ***US$'000***	2024 Continuing operations *US$'000*	2024 Discontinued operation *(note 15(a))* *US$'000*	2024 Total *US$'000*
Attributable to:							
Equity shareholders of the Company		**(233,849)**	**282,368**	**48,519**	(232,064)	18,021	(214,043)
Non-controlling interests		**(21,864)**	**11,772**	**(10,092)**	(71,076)	16,660	(54,416)
Profit/(loss) for the year		**(255,713)**	**294,140**	**38,427**	(303,140)	34,681	(268,459)
Earnings/(loss) per share	*8*						
Basic (in cents)		**(12.49)**	**15.08**	**2.59**	(12.67)	0.99	(11.68)
Diluted (in cents)		**(12.84)**	**14.36**	**1.52**	(13.14)	0.99	(12.15)

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

for the year ended 31 December 2025
(Expressed in United States dollars)

	2025			2024		
	Continuing operations	**Discontinued operation *(note 15(a))***	**Total**	Continuing operations	Discontinued operation *(note 15(a))*	Total
	US$'000	***US$'000***	***US$'000***	*US$'000*	*US$'000*	*US$'000*
Profit/(loss) for the year	**(255,713)**	**294,140**	**38,427**	(303,140)	34,681	(268,459)
Other comprehensive income for the year, net of tax						
Item that will not be reclassified to profit or loss:						
Remeasurement of net defined benefit liabilities	**850**	**–**	**850**	694	–	694
Items that may be reclassified subsequently to profit or loss:						
Exchange differences on translation of financial statements of foreign operations, net of nil tax	**33,307**	**4,653**	**37,960**	(15,292)	(2,335)	(17,627)
Share of other comprehensive income of equity-accounted investees	**235**	**–**	**235**	(1,062)	–	(1,062)
Other comprehensive income for the year	**34,392**	**4,653**	**39,045**	(15,660)	(2,335)	(17,995)
Total comprehensive income for the year	**(221,321)**	**298,793**	**77,472**	(318,800)	32,346	(286,454)
Attributable to:						
Equity shareholders of the Company	**(207,524)**	**284,724**	**77,200**	(243,513)	17,522	(225,991)
Non-controlling interests	**(13,797)**	**14,069**	**272**	(75,287)	14,824	(60,463)
Total comprehensive income for the year	**(221,321)**	**298,793**	**77,472**	(318,800)	32,346	(286,454)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(Expressed in United States dollars)

	Note	**31 December 2025**	31 December 2024
		US$'000	*US$'000*
Non-current assets			
Investment properties		**4,191**	4,214
Property, plant and equipment		**871,677**	934,159
		875,868	938,373
Intangible assets		**183,305**	234,317
Goodwill		**201,111**	188,514
Equity-accounted investees		**686,923**	382,861
Financial assets measured at fair value through profit or loss ("FVPL")		**6,997**	9,883
Derivative financial assets		**2,933**	–
Deferred tax assets		**21,550**	18,488
Other non-current assets		**84,455**	123,713
		2,063,142	1,896,149
Current assets			
Financial assets measured at FVPL		**19,904**	51,817
Inventories		**349,199**	379,288
Trade and other receivables	*9*	**468,967**	376,564
Pledged deposits and time deposits		**111,516**	213,509
Cash and cash equivalents	*10*	**682,508**	712,995
		1,632,094	1,734,173
Assets classified as held-for-sale		**1,439**	3,100
		1,633,533	1,737,273
Current liabilities			
Trade and other payables	*11*	**434,260**	638,997
Contract liabilities		**27,489**	19,863
Interest-bearing borrowings	*12*	**414,387**	318,066
Convertible bonds	*13*	**215,873**	147,133
Lease liabilities		**20,874**	40,143
Income tax payable		**16,129**	7,311
Derivative financial liabilities		**–**	7,500
		1,129,012	1,179,013
Net current assets		**504,521**	558,260
Total assets less current liabilities		**2,567,663**	2,454,409

	Note	31 December 2025 US$'000	31 December 2024 US$'000
Non-current liabilities			
Interest-bearing borrowings	*12*	**779,566**	757,711
Lease liabilities		**30,539**	47,932
Deferred income		**40,910**	51,491
Contract liabilities		**37,972**	26,948
Convertible bonds	*13*	**139,513**	374,224
Other payables		**13,800**	24,124
Derivative financial liabilities		**–**	5,534
Deferred tax liabilities		**25,190**	21,601
		1,067,490	1,309,565
NET ASSETS		**1,500,173**	1,144,844
CAPITAL AND RESERVES			
Share capital	*14*	**19**	18
Reserves		**980,796**	603,455
Total equity attributable to equity shareholders of the Company		**980,815**	603,473
Non-controlling interests		**519,358**	541,371
TOTAL EQUITY		**1,500,173**	1,144,844

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

for the year ended 31 December 2025

(Expressed in United States dollars)

	Note	**2025** ***US$'000***	2024 *US$'000*
Net cash generated from/(used in) operating activities		**69,132**	(49,669)
Net cash generated from/(used in) investing activities		**16,155**	(149,730)
Net cash used in financing activities		**(129,110)**	(97,919)
Net decrease in cash and cash equivalents		**(43,823)**	(297,318)
Cash and cash equivalents at 1 January		**712,995**	1,019,551
Effect of foreign exchange rate changes		**13,336**	(9,238)
Cash and cash equivalents at 31 December		**682,508**	712,995

1 Statement of compliance

These financial statements have been prepared in accordance with HKFRS Accounting Standards, which collective term includes all applicable individual Hong Kong Financial Reporting Standards ("HKFRSs"), Hong Kong Accounting Standards ("HKASs") and Interpretations issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and the disclosure requirements of the Hong Kong Companies Ordinance. These financial statements also comply with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). Material accounting policies adopted by the Group are disclosed below.

The HKICPA has issued certain new or amended HKFRS Accounting Standards that are first effective or available for early adoption for the current accounting period of the Group. Note 3 provides information on any changes in accounting policies resulting from initial application of these developments to the extent that they are relevant to the Group for the current accounting period reflected in these financial statements.

2 Basis of preparation of the financial statements

The consolidated financial statements for the year ended 31 December 2025 comprise the Company and its subsidiaries (together referred to as the "Group") and the Group's interest in equity-accounted investees.

Material uncertainty related to going concern

In determining the appropriate basis of preparation of the consolidated financial statements, the directors of the Company (the "Directors") are required to consider whether the Group could continue in operational existence for the foreseeable future.

As at 31 December 2025, the Group had (i) bank borrowings of US$414,387,000 due within 1 year (see note 12), and (ii) convertible bonds issued by the Company of US$215,873,000 which are due for early redemption in December 2026 (see note 13(b)).

In addition, certain non-current bank borrowings and convertible bonds amounting to US$750,049,000 (see notes 12 and 13) are subject to the fulfilment of covenants relating to certain of the Group's financial performance and ratios, including the Group's consolidated net profit being not less than (i) US$45 million for the half year ending 30 June 2026; and (ii) US$90 million for the year ending 31 December 2026. If the Group were to breach the covenants, these bank borrowings and part of the convertible bonds would be immediately repayable if requested by the lenders of these bank borrowings and the holders of the convertible bonds in accordance with the underlying facilities agreements. The occurrence of such circumstance may trigger the cross-default provisions of other borrowings of the Group and, as a possible consequence, these other borrowings may also be declared to be immediately due and repayable.

For the year ended 31 December 2025, the Group's continuing operations incurred a net loss of US$255,713,000.

Given the above, the liquidity of the Group is primarily dependent on (i) its ability to renew or refinance existing borrowings and to utilise its cash and cash equivalents available to the Group (see note 10) for repayment of its borrowings; and (ii) whether the above-mentioned financial covenants could be achieved. These conditions indicate the existence of a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern.

In view of these circumstances, the Directors have given consideration to the future liquidity of the Group and its available sources of finance in assessing whether the Group will have sufficient financial resources to continue as a going concern. The Directors have reviewed the Group's cash flow projections prepared by management, which covers a period of at least 12 months from 31 December 2025. Certain plans and measures have been taken to mitigate the liquidity pressures and to improve its financial position which include, but not limited to, the following:

(1) The Group has planned or implemented various strategies to improve the liquidity of the Group including to maintain more stringent cost control measure, substantially reduce the budget for operating costs, defer the plan for discretionary capital expenditure;

(2) The Group has plans to realise additional cash from disposal of certain equity accounted investees and other assets;

(3) The Group is in discussion with potential investors to make direct investment or to purchase equity interests in certain subsidiaries/equity-accounted investees of the Group; and

(4) The Group is in discussion with banks for the renewal of existing bank borrowings and obtaining new banking facilities.

The plans and measures as described above incorporate assumptions about future events and conditions. If the above plans and measures are successful, the Group will be able to generate sufficient financing and operating cash flows to meet its liquidity requirements for at least the next twelve months from the end of the reporting period. Based on the Directors' intentions and the cash flow forecast mentioned above, the Directors are of the opinion that it is appropriate to prepare the Group's consolidated financial statements for the year ended 31 December 2025 on a going concern basis. Should the Group not be able to continue to operate as a going concern, adjustments would have to be made to write down the value of assets to their recoverable amounts, to provide for further liabilities which might arise and to reclassify non-current assets and non-current liabilities as current assets and current liabilities respectively. The effect of these adjustments has not been reflected in these consolidated financial statements.

The measurement basis used in the preparation of the financial statements is the historical cost basis except that the following assets and liabilities are stated at their fair value:

– investments in debt and equity securities; and

– derivative financial instruments.

The preparation of financial statements in conformity with HKFRS Accounting Standards requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

3 Changes in accounting policies

The Group has applied amendments to HKAS 21, *The effects of changes in foreign exchange rates – Lack of exchangeability* issued by the HKICPA to these financial statements for the current accounting period. The amendments do not have a material impact on these financial statements as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

4 Revenue and segment reporting

(a) Revenue

(i) Disaggregation of revenue

Disaggregation of revenue from contracts with customers by major products or service lines is as follows:

	Continuing operations		**Discontinued operation**	
	2025	2024	**2025**	2024
	US$'000	*US$'000*	***US$'000***	*US$'000*
Revenue from contracts with customers within the scope of HKFRS 15				
– Sales of medical devices	**968,675**	899,773	**110,202**	106,415
– Others	**16,217**	16,489	**270**	279
	984,892	916,262	**110,472**	106,694
Revenue from other sources	**10,017**	8,107	**–**	–
	994,909	924,369	**110,472**	106,694

Disaggregation of revenue from contracts with customers by the timing of revenue recognition and by geographic markets is disclosed in notes 4(b)(i) and 4(b)(iii) respectively.

Revenue from each major customer which accounted for 10% or more of the Group's revenue is set out below:

	2025	2024
	US$'000	*US$'000*
Customer A	**145,805**	141,183
Customer B	**117,100**	N/A*

* Less than 10% of the Group's revenue in the respective years

(ii) Revenue expected to be recognised in the future arising from contracts with customers in existence at the reporting date

As at 31 December 2025, the aggregated amount of the transaction price allocated to the remaining performance obligation under the Group's existing contracts was US$45,507,000 (2024: US$34,354,000). This amount represents revenue expected to be recognised in the future from rendering post-sales services and extended warranty services. The Group will recognise the expected revenue in future when or as the service is rendered.

The Group has applied the practical expedient in paragraph 121 of HKFRS 15 such that the above information does not include information about revenue that the Group will be entitled to when it satisfies the remaining performance obligations under the contracts for sales of medical devices that had an original expected duration of one year or less.

(b) Segment reporting

The Group manages its businesses by divisions, which are organised by a mixture of both lines of business (products and services) and geography. In a manner consistent with the way in which information is reported internally to the Group's most senior executive management for the purposes of resource allocation and performance assessment, the Group has identified a number of reportable segments. No operating segments have been aggregated to form the following reportable segments.

Cardiovascular devices business	Sales, manufacture, research and development ("R&D") of cardiovascular devices.
Orthopedics devices business	Sales, manufacture, R&D of orthopedics devices.
CRM business	Sales, manufacture, R&D of cardiac rhythm management devices.
Endovascular and peripheral vascular devices business	Sales, manufacture, R&D of endovascular and peripheral vascular devices.
Neurovascular devices business	Sales, manufacture, R&D of neurovascular devices.
Structural heart disease business	Sales, manufacture, R&D of heart valve devices.
Surgical robot business	Sales, manufacture, R&D of surgical robot devices.

For the purposes of assessing segment performance and allocating resources between segments, the Group's senior executive management monitors the results, assets and liabilities attributable to each reportable segment on the following bases:

Segment assets include all current and non-current assets with the exception of corporate assets. Segment liabilities include liabilities directly attributable to the activities of each individual segment.

Revenue and expenses are allocated to the reportable segments with reference to sales generated by those segments and the expenses incurred by those segments or which otherwise arise from the depreciation or amortisation of assets attributable to those segments. Segment profit/(loss) includes the Group's share of profit/(loss) arising from the activities of the Group's equity-accounted investees that directly held by the respective reportable segment. However, other than reporting intersegment sales, assistance provided by one segment to another, including sharing of assets and technical know-how, is not measured.

The measure used for reporting segment profit/(loss) is "reportable segment net profit/(loss)". Items that are not specifically attributed to individual segments, such as unallocated exchange gain/(loss), unallocated corporate income and expenses, unallocated equity-settled share-based payment expenses and the People's Republic of China ("PRC") dividends withholding tax are excluded from segment net profit/(loss).

In addition to receiving segment information concerning reportable segment net profit/(loss), management is provided with segment information concerning revenue from external customers, interest income from bank deposits, interest expenses, depreciation and amortisation, impairment losses of non-current assets, ECLs on trade and other receivables and financial guarantee issued and additions to non-current segment assets used by the segments in their operations.

Disaggregation of revenue from contracts with customers by the timing of revenue recognition, as well as information regarding the Group's reportable segments as provided to the Group's most senior executive management for the purposes of resource allocation and assessment of segment performance for the years ended 31 December 2025 and 2024 is set out below.

(i) Segment results, assets and liabilities

	2025									
	Continuing operations								Discontinued operation	
	Cardiovascular devices business *US$'000*	Orthopedics devices business *US$'000*	Cardiac rhythm management business *US$'000*	Endovascular and peripheral vascular devices business *US$'000*	Structural heart disease business *US$'000*	Surgical robot business *US$'000*	Others* *US$'000*	Subtotal *US$'000*	Neurovascular devices business *US$'000*	Total *US$'000*
Disaggregated by timing of revenue recognition										
Point in time	180,251	232,400	220,221	187,855	42,717	21,393	92,728	977,565	110,202	1,087,767
Over time	1,500	2,358	9,479	–	–	1,126	2,881	17,344	270	17,614
Revenue from external customers	181,751	234,758	229,700	187,855	42,717	22,519	95,609	994,909	110,472	1,105,381
Intersegment revenue	430	397	19	1,626	8,597	55,056	–	66,125	564	66,689
Reportable segment revenue	182,181	235,155	229,719	189,481	51,314	77,575	95,609	1,061,034	111,036	1,172,070
Reportable segment net profit/(loss)	28,506	(18,365)	(118,401)	77,700	(17,693)	(37,612)	(62,540)	(148,405)	25,670	(122,735)
Interest income from bank deposits	662	119	225	1,575	6,940	942	10	10,473	2,067	12,540
Interest expense	6,384	4,901	28,882	284	1,144	2,661	924	45,180	172	45,352
Depreciation and amortisation for the year	24,949	24,847	15,624	12,605	12,947	15,274	17,436	123,682	8,557	132,239
Provision for/(reversal of) impairment of:										
– Property, plant and equipment	–	–	2,054	–	–	5,091	14,000	21,145	–	21,145
– Equity-accounted investees	–	–	–	–	–	(420)	16,100	15,680	8,303	23,983
– Intangible assets	11,000	–	6,900	–	–	–	1,497	19,397	–	19,397
– Goodwill	–	–	–	–	–	211	–	211	–	211
– Trade and other receivables	85	579	351	1,220	–	–	–	2,235	–	2,235
Reportable segment assets	479,075	555,916	331,974	660,101	338,383	189,847	444,915	3,000,211	–	3,000,211
Additions to non-current segment assets during the year	12,127	17,553	12,469	54,232	3,557	5,603	35,328	140,869	24,718	165,587
Reportable segment liabilities	408,798	434,769	331,733	76,501	67,618	131,190	142,988	1,593,597	–	1,593,597

	2024 (Re-presented)									
	Continuing operations								Discontinued operation	
	Cardiovascular devices business *US$'000*	Orthopedics devices business *US$'000*	Cardiac rhythm management business *US$'000*	Endovascular and peripheral vascular devices business *US$'000*	Structural heart disease business *US$'000*	Surgical robot business *US$'000*	Others* *US$'000*	Subtotal *US$'000*	Neurovascular devices business *US$'000*	Total *US$'000*
Disaggregated by timing of revenue recognition										
Point in time	160,140	249,565	212,129	167,918	48,902	22,158	47,909	908,721	106,415	1,015,136
Over time	1,040	2,880	8,456	–	–	375	2,897	15,648	279	15,927
Revenue from external customers	161,180	252,445	220,585	167,918	48,902	22,533	50,806	924,369	106,694	1,031,063
Intersegment revenue	4,555	261	28	1,619	1,795	13,489	918	22,665	287	22,952
Reportable segment revenue	165,735	252,706	220,613	169,537	50,697	36,022	51,724	947,034	106,981	1,054,015
Reportable segment net profit/(loss)	(18,167)	(26,268)	(88,460)	69,238	(7,485)	(90,927)	(97,048)	(259,117)	34,968	(224,149)
Interest income from bank deposits	1,545	147	783	2,407	10,473	309	388	16,052	2,230	18,282
Interest expense	5,924	10,821	32,207	232	514	2,778	5,233	57,709	496	58,205
Depreciation and amortisation for the year	23,354	27,193	16,224	9,845	13,132	16,559	19,981	126,288	8,481	134,769
Provision for/(reversal of) impairment of:										
– Property, plant and equipment	–	–	–	–	–	–	4,428	4,428	–	4,428
– Equity-accounted investees	–	–	–	–	(11,526)	16,365	–	4,839	–	4,839
– Intangible assets	–	–	–	–	–	–	31,339	31,339	–	31,339
– Goodwill	13,430	–	–	–	–	–	4,157	17,587	–	17,587
– Trade and other receivables	–	236	–	456	–	–	837	1,529	–	1,529
Reportable segment assets	465,775	509,802	360,720	597,017	373,009	178,488	519,604	3,004,415	284,447	3,288,862
Additions to non-current segment assets during the year	14,431	31,795	11,165	121,202	72,875	10,126	35,062	296,656	9,885	306,541
Reportable segment liabilities	370,798	408,113	524,126	67,179	62,722	140,612	217,339	1,790,889	46,392	1,837,281

Note: The comparative information of segment reporting has been re-presented to reflect the changes in allocation of resources and assessment of performance.

Revenues and results from segments below the quantitative thresholds are mainly attributable to non-vascular interventional devices business, surgical devices business and fermentation-based active pharmaceutical ingredients business, etc. None of those segments individually met any of the quantitative thresholds for reportable segments.

(ii) Reconciliation of reportable segment profit or loss, assets and liabilities

	2025	2024
	US$'000	*US$'000*
Profit or loss		
Reportable segment net loss	**(122,735)**	(224,149)
Share awards scheme	**(3,417)**	(2,585)
Other equity-settled share-based payment expenses	**(10,084)**	(13,966)
Interest expenses on convertible bonds issued by the Company	**(42,930)**	(33,416)
Unallocated exchange loss	**(6,011)**	(3,748)
Impairment losses of non-current assets	**(42,514)**	(28,358)
Gain on disposal of subsidiaries, net of tax	**326,540**	98,155
Unallocated expenses, net	**(60,422)**	(60,392)
Consolidated profit/(loss) for the year	**38,427**	(268,459)

	2025	2024
	US$'000	*US$'000*
Assets		
Reportable segment assets	**3,000,211**	3,288,862
Elimination	**(167,196)**	(182,996)
Unallocated corporate assets:		
– Cash and cash equivalents	**131,084**	95,171
– Pledged and time deposits	**1,092**	30,598
– Equity-accounted investees	**569,653**	240,296
– Property, plant and equipment	**112,423**	124,397
– Others	**49,408**	37,094
Consolidated total assets	**3,696,675**	3,633,422
Liabilities		
Reportable segment liabilities	**1,593,597**	1,837,281
Elimination	**(120,773)**	(136,033)
Convertible bonds	**355,386**	369,945
Interest-bearing borrowings	**340,051**	386,164
Lease liabilities	**2,677**	9,046
Unallocated corporate liabilities	**25,564**	22,175
Consolidated total liabilities	**2,196,502**	2,488,578

(iii) Geographic information

The following table sets out information about the geographical location of (i) the Group's revenue from external customers and (ii) the Group's investment property, property, plant and equipment, intangible assets, goodwill and investments in equity-accounted investees ("specified non-current assets"). The geographical location of customers is based on the location at which the goods are delivered and services are rendered. The geographical location of the specified non-current assets is based on the physical location of the asset, in the case of property, plant and equipment, the location of the operation to which they are allocated, in case of goodwill and intangible assets, and the location of operations, in case of investments in equity-accounted investees.

	Continuing operations		**Discontinued operation**	
	2025	2024	**2025**	2024
	US$'000	*US$'000*	***US$'000***	*US$'000*
Revenues from external customers				
The PRC (country of domicile)	**421,470**	425,710	**97,478**	96,401
North America	**79,579**	90,724	**2,694**	1,683
Europe	**325,950**	278,332	**2,681**	1,920
Asia (excluding the PRC)	**108,927**	85,665	**3,223**	2,610
South America	**42,325**	29,342	**4,396**	4,080
Others	**16,658**	14,596	**–**	–
	994,909	924,369	**110,472**	106,694

	31 December	31 December
	2025	2024
	US$'000	*US$'000*
Specified non-current assets		
The PRC (country of domicile)	**1,516,995**	1,285,224
North America	**145,104**	149,901
Europe	**260,128**	272,621
Asia (excluding the PRC)	**22,601**	35,542
South America	**2,379**	491
Others	**–**	286
	1,947,207	1,744,065

5 Other net income

	Continuing operations		Discontinued operation	
	2025	2024	**2025**	2024
	US$'000	*US$'000*	***US$'000***	*US$'000*
Government grants*	**19,547**	16,960	**5,066**	4,234
Interest income on financial assets measured at amortised cost	**14,577**	20,229	**2,142**	2,519
Net gain/(loss) on disposal of property, plant and equipment	**3,921**	(2,495)	**–**	15
Net foreign exchange gain/(loss)	**8,257**	(12,195)	**140**	(139)
Others	**1,345**	248	**–**	(17)
	47,647	22,747	**7,348**	6,612

* Majority of the government grants are subsidies received from government for the encouragement of R&D projects.

6 Profit/(loss) before taxation

Profit/(loss) before taxation is arrived at after charging/(crediting):

(a) Finance costs

	Continuing operations		Discontinued operation	
	2025	2024	**2025**	2024
	US$'000	*US$'000*	***US$'000***	*US$'000*
Interest on the convertible bonds	**43,027**	33,523	**–**	–
Interest on interest-bearing borrowings	**36,229**	36,193	**–**	–
Interest on preferred shares issued by subsidiaries *(note 11(ii))*	**24,446**	27,671	**–**	–
Interest on lease liabilities	**5,204**	6,637	**165**	325
Total interest expense on financial liabilities not at fair value through profit or loss	**108,906**	104,024	**165**	325
Less: interest expense capitalised into properties under development	**(2,252)**	(2,113)	**–**	–
Add: fee charges and others	**4,607**	3,998	**57**	170
	111,261	105,909	**222**	495

(b) Other operating costs

	Continuing operations		Discontinued operation	
	2025	2024	**2025**	2024
	US$'000	*US$'000*	***US$'000***	*US$'000*
Legal and professional service fee	**10,243**	1,632	**–**	–
Donations	**4,540**	5,734	**282**	125
Others	**16,724**	5,769	**–**	–
	31,507	13,135	**282**	125

(c) Other items

	Continuing operations		Discontinued operation	
	2025	2024	**2025**	2024
	US$'000	*US$'000*	***US$'000***	*US$'000*
Amortisation of intangible assets	**23,096**	18,956	**2,426**	2,305
Depreciation charge				
– owned property, plant and equipment	**79,133**	90,415	**2,696**	2,866
– right-of-use assets	**39,913**	42,264	**3,409**	3,487
Less: Amounts capitalised as development costs	**(576)**	(547)	**(392)**	(234)
Total amortisation and depreciation	**141,566**	151,088	**8,139**	8,424
Impairment losses on non-current assets:				
– property, plant and equipment	**23,079**	5,741	**–**	–
– intangible assets	**19,397**	31,339	**–**	–
– goodwill	**211**	17,587	**–**	–
– equity-accounted investees	**56,260**	33,197	**8,303**	–
	98,947	87,864	**8,303**	–

7 Income tax in the consolidated statement of profit or loss

(a) Taxation in the consolidated statement of profit or loss represents:

	Continuing operations		Discontinued operation	
	2025	2024	**2025**	2024
	US$'000	*US$'000*	***US$'000***	*US$'000*
Current tax – PRC Corporate Income Tax ("CIT")				
Provision for the year	**19,829**	16,184	**15,631**	8,617
(Over)/under-provision in respect of prior years	**(26)**	11,583	**–**	–
	19,803	27,767	**15,631**	8,617
Current tax – other jurisdictions	**5,018**	5,648	**–**	–
Total current tax	**24,821**	33,415	**15,631**	8,617
Deferred tax				
Origination and reversal of temporary differences	**(1,598)**	2,689	**(858)**	(1,047)
	23,223	36,104	**14,773**	7,570

Pursuant to the CIT Law of the PRC, all of the Company's PRC subsidiaries are subject to PRC CIT at a rate of 25% except for those subsidiaries entitled to a preferential income tax rate of 15% as they are certified as "High and New Technology Enterprise" ("HNTE"). According to Guoshuihan [2009] No. 203, HNTE is entitled to a preferential income tax rate of 15% during the certified period.

Taxation for overseas subsidiaries is calculated using the estimated annual effective tax rate applicable in the relevant jurisdictions.

(b) Pillar Two income tax

From 1 January 2024, many countries, including Japan and many European Union member states, adopted a global minimum effective tax rate of 15% based on the Pillar Two framework issued by the Organisation for Economic Cooperation and Development ("OECD"). From 1 January 2025, the Group is also liable to Pillar Two income taxes under the Hong Kong Inland Revenue (Amendment) (Minimum Tax for Multinational Enterprise Groups) Ordinance 2025 for its earnings in the Hong Kong SAR and certain other jurisdictions where a domestic minimum top-up tax has not been implemented, including the Chinese Mainland. Other countries where the Group does business are also actively considering adopting the framework or are in various stages of enacting the framework into their country's laws. The Group continues to monitor legislative adoption of the Pillar Two rules by country, as well as for additional guidance from the OECD. The Group considers the current impact of the adoption of a global minimum effective tax is not material.

8 Earnings/(loss) per share

(a) Basic earnings/(loss) per share

The calculation of basic earnings/(loss) per share is based on the profit attributable to ordinary equity shareholders of the Company of US$48,519,000 (2024: loss of US$214,043,000) and the weighted average number of ordinary shares of 1,872,418,000 shares (2024: 1,831,792,000 shares) in issue during the year, calculated as follows:

(i) Weighted average number of ordinary shares

	2025	2024
	'000	*'000*
Issued ordinary shares at 1 January	**1,846,725**	1,834,477
Effect of share options exercised	**9,867**	2,261
Effect of treasury shares held	**(1,952)**	(4,946)
Effect of conversion of convertible loans	**17,778**	–
Weighted average number of ordinary shares at 31 December	**1,872,418**	1,831,792

(b) Diluted earnings/(loss) per share

The calculation of diluted earnings/(loss) per share is based on the profit attributable to ordinary equity shareholders of the Company of US$29,888,000 (2024: loss of US$222,591,000) and the weighted average number of ordinary shares of 1,966,530,000 shares (2024: 1,831,792,000 shares) after adjusting the effects of dilutive potential issuable ordinary shares under a put option granted to Sino Rhythm Limited ("SRL") that may be settled in ordinary shares of the Company, calculated as follows.

(i) Profit/(loss) attributable to ordinary equity shareholders of the Company (diluted)

	2025	2024
	US$'000	*US$'000*
Profit/(loss) attributable to ordinary equity shareholders	**48,519**	(214,043)
Effect of deemed exercise of put option granted to SRL in respect of share repurchase obligation	**(18,631)**	(8,548)
Profit/(loss) attributable to ordinary equity shareholders (diluted)	**29,888**	(222,591)

(ii) Weighted average number of ordinary shares (diluted)

	2025	2024
	'000	*'000*
Weighted average number of ordinary shares at 31 December	**1,872,418**	1,831,792
Effect of deemed exercise of put option granted to SRL in respect of share repurchase obligation	**94,112**	–
Weighted average number of ordinary shares at 31 December (diluted)	**1,966,530**	1,831,792

(iii) Consolidated profit/(loss) attributable to ordinary equity shareholders of the Company (diluted):

	2025	2024
	US$'000	*US$'000*
Profit/(loss) attributable to equity shareholders (diluted)		
– from continuing operations	**(252,480)**	(240,612)
– from discontinued operation	**282,368**	18,021
	29,888	(222,591)

(iv) Earnings/(loss) per share (diluted):

	2025	2024
Earnings/(loss) per share (diluted) (in cents)		
– from continuing operations	**(12.84)**	(13.14)
– from discontinued operation	**14.36**	0.99
	1.52	(12.15)

Save as disclosed above, the calculation of diluted earnings/(loss) per share amount for the year ended 31 December 2025 has not included the potential effects of the deemed issue of shares under the share option schemes adopted by the Company and the deemed conversion of the convertible bonds/loans issued by the Company (see note 13) into ordinary shares during the year and neither included the effects of potential ordinary shares in or issued by subsidiaries and equity-accounted investees of the Group, as they had anti-dilutive effects on the basic earnings/(loss) per share amount.

9 Trade and other receivables

	31 December 2025	31 December 2024
	US$'000	*US$'000*
Trade receivables due from:		
– third party customers	**333,182**	278,568
– related parties	**14,475**	8,075
	347,657	286,643
Less: Loss allowance	**(19,587)**	(21,007)
Trade receivables, net of loss allowance	**328,070**	265,636
Other debtors	**44,458**	39,064
Amounts due from a related party in relation to transfer of non-current assets	**795**	777
Consideration receivable in relation to disposal of subsidiaries	**498**	7,167
Income tax recoverable	**5,716**	930
Deposits and prepayments	**89,430**	62,990
	468,967	376,564

All of the above trade and other receivables are expected to be recovered or recognised as expense within one year.

Ageing analysis

As of the end of the reporting period, the ageing analysis of trade debtors (which are included in trade and other receivables), based on the invoice date and net of loss allowance, is as follows:

	2025	2024
	US$'000	*US$'000*
Within 1 month	**148,861**	126,052
1 to 3 months	**108,158**	79,739
3 to 12 months	**57,297**	53,045
More than 12 months	**13,754**	6,800
	328,070	265,636

10 Cash and cash equivalents

As at 31 December 2025, the balance of the deposits in the designated bank accounts of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (上海微創心脈醫療科技(集團)股份有限公司, "ME Endo") is US$141,581,000 (2024: US$181,422,000) which is not available for general usage and could only be used for purposes specified in the IPO and placing prospectus of MP Endo.

Apart from the above, as at 31 December 2025, cash and cash equivalents situated in Chinese Mainland amounted to US$377,520,000 (2024: US$434,054,000), which are not freely remissible to the Company as the remittance of funds out of Chinese Mainland is subject to relevant rules and regulations of foreign currency exchange control.

11 Trade and other payables

	31 December 2025	31 December 2024
	US$'000	*US$'000*
Current		
Trade payables due to:		
– third party suppliers	**152,734**	150,134
– related parties	**23,917**	24,446
Total trade payables (i)	**176,651**	174,580
Share repurchase obligations (ii)	**–**	240,690
Consideration payables in connection with the acquisition of subsidiaries (iii)	**5,879**	952
Other payables and accrued charges	**251,730**	222,775
	434,260	638,997
Non-current		
Share repurchase obligations (ii)	**–**	6,258
Consideration in connection with the acquisition of a subsidiary (iii)	**–**	4,935
Net defined benefit obligation	**10,305**	10,184
Other payables	**3,495**	2,747
	13,800	24,124

All current trade and other payables are expected to be settled within one year or are repayable on demand.

Notes:

(i) As of the end of the reporting period, the ageing analysis of the trade payables based on invoice date is as follows:

	2025	2024
	US$'000	*US$'000*
Within 1 month	**102,463**	93,869
Over 1 month but within 3 months	**33,378**	24,925
Over 3 months but within 6 months	**14,399**	19,652
Over 6 months but within 1 year	**15,430**	4,249
Over 1 year	**10,981**	31,885
	176,651	174,580

(ii) Share repurchase obligations

The share repurchase obligations borne by MicroPort Cardiac Rhythm Management Limited ("CRM Cayman") are terminated as a result of a restructuring as disclosed in note 15(b).

Movements of the share repurchase obligations arising from these shares are as follows:

	Preferred shares issued by CRM Cayman	**Redemption rights issued by other subsidiary**	**Total**
	US$'000	***US$'000***	***US$'000***
As at 1 January 2025	**240,690**	**6,258**	**246,948**
Charge to finance costs *(note 6(a))*	**24,143**	**303**	**24,446**
Derecognition in relation to the disposal of a subsidiary	**–**	**(6,425)**	**(6,425)**
Derecognition in relation to the restructuring of CRM business *(note 15(b))*	**(264,833)**	**–**	**(264,833)**
Exchange adjustments	**–**	**(136)**	**(136)**
At 31 December 2025	**–**	**–**	**–**

(iii) Consideration in business combinations

The consideration payable in connection with the acquisition of subsidiaries primarily includes the contingent consideration payable to the former shareholders of Hemovent, subject to certain milestones and conditions within 5 years from October 2021. The contingent consideration is measured at fair value with subsequent changes charged into profit or loss.

12 Interest-bearing borrowings

As of the end of the reporting period, the interest-bearing borrowings were repayable as follows:

	2025	2024
	US$'000	*US$'000*
Within 1 year or on demand	**414,387**	318,066
After 1 year but within 2 years	**335,449**	321,805
After 2 years but within 5 years	**360,596**	331,492
After 5 years	**83,521**	104,414
	779,566	757,711
	1,193,953	1,075,777

As of the end of the reporting period, the interest-bearing borrowings were secured as follows:

	2025	2024
	US$'000	*US$'000*
Bank loans		
– secured	**750,157**	556,319
– unsecured	**443,796**	519,458
	1,193,953	1,075,777

At 31 December 2025, the bank loans totaling US$750,157,000 (31 December 2024: US$556,319,000) were secured by (i) the land use rights and buildings held for own use with net book values of US$12,931,000 and US$234,127,000, respectively (31 December 2024: land use rights of US$12,585,000 and buildings held for own use of US$267,903,000, respectively); (ii) the Group's equity interest in several subsidiaries, and (iii) certain patents held by the Group, whose carrying value is nil as they have not been capitalised as intangible assets.

Part of the Group's non-current bank loans amounting to US$610,536,000 (31 December 2024: US$439,851,000) are subject to the fulfilment of covenants relating to certain financial targets or ratios, as are commonly found in lending arrangements with financial institutions. If the Group were to breach the covenants, the drawn down facilities would become payable on demand. The occurrence of such circumstance may trigger the cross-default provisions of other borrowings available to the Group and, as a possible consequence, these other borrowings may also be declared to be immediately due and payable. The Group regularly monitors its compliance with these covenants. As at 31 December 2025 and 2024, none of the covenants relating to drawn down facilities had been breached.

13 Convertible bonds

	2025	2024
	US$'000	*US$'000*
Convertible bonds issued by CRM Cayman	**–**	147,133
Convertible bonds/loans issued by the Company	**355,386**	369,945
Convertible bonds issued by a subsidiary	**–**	4,279
	355,386	521,357

Representing

Current portion	**215,873**	147,133
Non-current portion	**139,513**	374,224
	355,386	521,357

(a) Convertible bonds issued by CRM Cayman (the "CRM Convertible Bonds")

In October 2022, CRM Cayman issued the CRM Convertible Bonds with a principal amount of US$90 million to several external investors. The maturity date of the CRM Convertible Bonds is 14 October 2025, and each bondholder may, in its sole discretion, exercise a one-time option to extend the maturity date for two years. The holders have the right to convert any portion of the CRM Convertible Bonds into shares of CRM Cayman at any time on or after the issue date based on the enterprise value of the CRM Cayman, being US$1.25 billion (subject to adjustments).

In 2025, the outstanding CRM Convertible Bonds were fully redeemed by CRM Cayman at a cash consideration of US$170,080,000.

The movement of the CRM Convertible Bonds during the year is as follows:

	2025	2024
	US$'000	*US$'000*
Balance at 1 January	**147,133**	92,836
Changes in fair value recognised in profit or loss during the year	**32,211**	19,262
Interests paid	**(9,264)**	(10,661)
Issued during the year	**–**	45,696
Redemption during the year	**(170,080)**	–
Balance at 31 December	**–**	147,133

(b) Convertible bonds/loans issued by the Company

(i) Convertible bonds issued by the Company due in 2028 (the "2028 Convertible Bonds")

In December 2023, the Company issued the 2028 Convertible Bonds with a principal amount of US$220 million, which are listed on the Stock Exchange. The 2028 Convertible Bonds bear an interest rate of 5.75% per annum and the interests are payable semi-annually.

Pursuant to the terms of the 2028 Convertible Bonds, the bondholders could convert part of or the entire outstanding bond balances at the option of the bondholders into fully paid ordinary shares of the Company at an initial conversion price of HK$12.7790 per share, subject to the adjustment under certain terms and conditions at the fixed exchange rate of HK$7.8148 to US$1 before the maturity date.

The maturity date of the 2028 Convertible Bonds is 19 December 2028 and the Company shall redeem the 2028 Convertible bonds at its principal amount together with accrued and unpaid interests. In addition, the bondholders also have a right to require the Company to redeem entire or partial of the 2028 Convertible Bonds on 21 December 2026 at their principal amount together with interest accrued but unpaid.

The 2028 Convertible Bonds are accounted for as compound financial instruments which contain both a liability component and an equity component with an accounting treatment similar to the 2026 Convertible Bonds.

As at 31 December 2024 and 2025, the outstanding principal of the 2026 Convertible Bonds was US$220 million. The carrying value of the liability component of the 2028 Convertible Bonds was US$215,873,000 as at 31 December 2025.

No conversion of the 2028 Convertible Bonds had occurred up to 31 December 2025.

(ii) Convertible loans issued by the Company due in 2029 (the "2029 Convertible Loans")

In April 2024, the Company entered into a convertible facility agreement (the "Convertible Facility Agreement") with four lenders (the "Original Lenders"), pursuant to which, the Original Lenders agreed to make available to the Company a convertible term loan facility in an aggregate principal amount of US$150 million, with an accordion option to increase the total commitments by an aggregate principal amount of up to US$50 million.

The 2029 Convertible Loans bear interest at of 5.75% per annum. The lender could convert part of or the entire outstanding balances into fully paid ordinary shares of the Company at an initial conversion price of HK$7.46 per share, subject to the adjustment under certain terms and conditions at the fixed exchange rate of HK$7.8285 to US$1 before the maturity date.

The Company shall repay the 2029 Convertible Loans in 2029, together with all interest, a premium, being 40% of the outstanding principal and any accrued but unpaid amounts payable to the lenders.

In addition, pursuant to the terms of the 2029 Convertible Loans, in May 2027, the lenders have right to require the Company to redeem all 2029 Convertible Loans, together with all interest, a premium, being 30% of the outstanding principal and any accrued but unpaid amounts payable to the lenders. At any time after May 2027, the Company could redeem all 2029 Convertible Loans, together with all interest, a premium, being 40% of the outstanding principal and any accrued but unpaid amounts payable to the lenders, provided that the closing price of the ordinary shares of the Company for each of any 20 trading days within a period of 30 consecutive trading days, the last of which occurs not more than 5 trading days prior to the publishing date of such notice, is at least 130% of the conversion price, subject to further adjustments.

The Company shall also attain certain performance targets, failing which the lenders may require the Company to apply an amount equal to US$50,000,000 towards prepayment of the 2029 Convertible Loans and payment of all accrued interest on the prepayment amount and a premium, being 30% of the prepayment amount.

The 2029 Convertible Loans are accounted for as compound financial instruments which contain a debt component, derivative components and an equity component. The debt component is initially measured as the present value of the future cash flows, discounted at the market rate of interest applicable at the time of initial recognition to similar liabilities that do not have a conversion option. The derivative components represent the aforesaid early redemption rights granted to the lenders and the Company and are initially measured at fair value. Any excess of proceeds over the amount initially recognised as the debt components and derivative components is recognised as the equity component. The debt component is subsequently carried at amortised cost. The interest expenses recognised in profit or loss on the debt component is calculated using the effective interest method. Changes in the fair value of the derivative components are recognised in profit or loss. The equity component is recognised in the capital reserve until the 2029 Convertible Loans are either converted or redeemed.

As at 31 December 2024, the outstanding principal of the 2029 Convertible Loans was US$200 million.

In 2025, part of the 2029 Convertible Loans with a principal amount of US$41.5 million were converted into 43,549,965 new issued ordinary shares of the Company in accordance with the terms and conditions of the Convertible Facility Agreement.

As at 31 December 2025, the outstanding principal of the 2029 Convertible Loans was US$158.5 million. The carrying value of the liability component of the 2029 Convertible Loans was US$139,513,000 as at 31 December 2025.

The 2029 Convertible Loans are secured by (i) assignment by way of security of certain intercompany loan(s) by the Company; (ii) security over a property located in the US with a carrying value of approximately US$44.8 million as at 31 December 2025; and (iii) share mortgage in respect of all issued ordinary shares of two subsidiaries.

(iii) Movement of the convertible bonds/loans issued by the Company during the year

	Derivative component *US$'000*	Liability component *US$'000*	Equity component *US$'000*	Total *US$'000*
At 1 January 2025	**5,534**	**369,945**	**83,651**	**459,130**
Interest charged	**–**	**42,930**	**–**	**42,930**
Interest paid	**–**	**(22,957)**	**–**	**(22,957)**
Changes in fair value recognised in profit or loss during the year	**(8,467)**	**–**	**–**	**(8,467)**
Conversion during the year	**–**	**(34,532)**	**(6,855)**	**(41,387)**
At 31 December 2025	**(2,933)**	**355,386**	**76,796**	**429,249**

14 Capital, reserves and dividends

(a) Dividends

The Directors did not propose any payment of final dividend in respect of the previous year during the year ended 31 December 2025 (2024: nil).

The Directors did not propose any payment of final dividend for the year ended 31 December 2025 (2024: nil).

(b) Share capital

(i) Ordinary shares

	2025		2024	
	Number of shares *'000*	Amount *US$'000*	Number of shares *'000*	Amount *US$'000*
Authorised:				
Ordinary shares of US$0.00001 each	**5,000,000**	**50**	5,000,000	50
Ordinary shares, issued and fully paid:				
At 1 January	**1,846,725**	**18**	1,834,477	18
Shares issued under share schemes	**22,672**	**–**	12,248	–
Shares issued in respect of the conversion of convertible loans	**43,550**	**1**	–	–
At 31 December	**1,912,947**	**19**	1,846,725	18

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. All ordinary shares rank equally with regard to the Company's residual assets.

(ii) Purchase of own shares

During the year ended 31 December 2025, the Company did not purchase its own ordinary shares (2024: 1,877,400 ordinary shares) through the designated trustees under the share award scheme.

Repurchased shares held at the end of the reporting period under the share award scheme are classified as treasury shares and are presented as a decrease in the capital reserve.

At 31 December 2025, the trustee under a long-term benefit plan held 172,000 ordinary shares of the Company (31 December 2024: 172,000 ordinary shares). These shares are treated as plan assets and carried at fair value with reference to the share price of ordinary shares of the Company, which are presented as a deduction of non-current defined benefit obligation.

(iii) Shares issued under the share schemes

During the year ended 31 December 2025, 22,671,935 (2024: 12,248,341) share options were exercised to subscribe for 22,671,935 (2024: 12,248,341) ordinary shares in the Company at a total consideration of US$12,867,000 (2024: US$5,187,000), of which nil (2024: nil) and US$12,867,000 (2024: US$5,187,000) was credited to share capital and share premium, respectively. In addition, an amount of US$32,023,000 (2024: US$1,635,000) was transferred from the capital reserve to the share premium.

15 Disposal or dilution of interests in subsidiaries

(a) Disposal or dilution results in a loss of control

(i) MP Neuro

In December 2025, the Group transferred certain equity interest in MP Neuro to several third-party investors, upon completion of which the Group's equity interests in MP Neuro were approximately 39%. In addition, due to an appointment of a new director of MP Neuro in December 2025, the Group could no longer control the board of MP Neuro. Management consider the Group has lost control over MP Neuro and ceased to consolidate MP Neuro in its consolidated financial statements.

As the operation of MP Neuro is considered as separate major line of business, management accounted for the operations of MP Neuro as a discontinued operation in the consolidated financial statements for the year ended 31 December 2025.

A gain on disposal of US$276,893,000 was recognised in profit or loss and the Group's remaining equity interest in MP Neuro was recognised as an equity-accounted investee.

(b) Disposal or dilution without losing control

(i) Restructuring of CRM business

In December 2025, the Group completed a restructuring of CRM business, pursuant to which, all the existing issued ordinary and preferred shares of CRM Cayman were cancelled in exchange for newly issued ordinary shares of MicroPort CardioFlow Medtech Corporation ("**MP CardioFlow**"). Upon the completion of the restructuring, CRM Cayman became a wholly-owned subsidiary of MP CardioFlow and the Group's equity interest in MP CardioFlow decreased from approximately 48% as at 31 December 2024 to approximately 45% (considering the effect of treasury shares). The Directors consider the Group retains control over MP CardioFlow.

The restructuring of CRM business was treated as equity transactions. The difference between (i) the sum of the carrying value of preferred shares (note 11) and the derivative financial liabilities; and (ii) the carrying amount of net assets in proportion of the diluted equity interests in MP CardioFlow, was credit to capital reserve of the Group.

Further details of the restructuring are set out in the Company's announcements dated 16 July 2025, 29 September 2025 and 15 December 2025.

BUSINESS REVIEW

Overview

In 2025, the global economy moved forward amidst multiple challenges, including geopolitical tensions, evolving trade landscapes, and rising protectionism, which exerted pressure on growth momentum and market confidence. The Chinese economy demonstrated strong resilience through a profound transformation, consistently driving development toward new frontiers and industries toward optimization by focusing on the cultivation of "new quality productive forces", further highlighting the core tenets of high-quality development.

Against this macroeconomic backdrop, the demand foundation for the global medical device industry remained solid. The trend of population aging and the public's pursuit of improved health levels provided sustained rigid demand for the industry. Simultaneously, technological advancements are driving medical diagnosis and treatment toward more precise and intelligent directions, continuously opening new paths to enhance patient outcomes and quality of life. In China, the policy environment for the industry has continued to refine, establishing a clear institutional foundation for high-quality industrial development. Centralized volume-based procurement ("VBP") has continued to optimize during its normalized implementation. Through the introduction of guidelines such as "stabilizing clinical practice and ensuring quality" and innovative mechanisms like "anchor pricing", the National Healthcare Security Administration ("NHSA") is committed to creating a benign competitive environment. This marks that VBP has become a core engine for driving industry efficiency, guiding optimized resource allocation, and fostering industrial innovation and upgrading. Furthermore, the improvement of the multi-level medical security system and the reform of payment methods have progressed in synergy, aiming to better satisfy diversified health needs and providing clear guidance and broad space for the high-quality development of innovative drugs and medical devices.

Facing a complex and volatile global external environment, the Group has consistently maintained its strategic focus and demonstrated operational resilience. For the full year, the Group recorded a total revenue of US$1,105.4 million, representing a year-on-year increase of 6.0% (excluding the foreign exchange impact). Core business segments all achieved steady market penetration.

Most importantly, during the Reporting Period, the Group recorded a net profit of US$38.4 million, achieving a turnaround from loss to profit overall, steering organic growth onto a healthy trajectory, and proactively implementing strategic adjustments. Among these, the recovery of operating profit was crucial, validating the enhanced operational quality and sustainability of the Group. Specifically:

- Non-GAAP profit achieved a critical turnaround to positive: Representing an increase of US$123.5 million compared to the full year of 2024, validating the high quality and intrinsic value of our organic growth.

- Continuous improvement in gross profit level: Through supply chain integration and process optimization, the gross margin increased by 1.7 percentage points year-on-year, and the gross profit amount increased by US$60.5 million compared to the full year of 2024.

- Significant results in operations: The total amount of the three major operating expenses decreased by 9.0% year-on-year, the operating expense ratio (calculated as the sum of research and development costs, distribution costs and administrative expenses, divided by revenue) was optimized by 10.3 percentage points year-on-year, and the operating expenses decreased by US$63.1 million compared to the full year of 2024.

As an international high-end medical device group rooted in China, our innovative products have benefited more than 20,000 hospitals in over 100 countries and regions worldwide. Our globalization process has reached a new level, with the advantages of the "GloMatrix" platform becoming increasingly prominent:

- During the Reporting Period, the fully upgraded "GloMatrix" platform drove a year-on-year increase of 78.8% (excluding the foreign exchange impact) in related business revenue, reaching US$163.9 million. Overseas revenues from several core segments, such as surgical robots and structural heart diseases, recorded rapid growth, further demonstrating the advantages of platform synergy.

- Based on economies of scale and excellent operational efficiency, the platform achieved break-even during the Reporting Period, and its future profitability is expected to continue to strengthen as the scale expands.

During the Reporting Period, the Group successfully advanced core optimizations in corporate governance, establishing a solid foundation for long-term steady growth:

- Restructuring of business architecture: During the Reporting Period, the Group completed the strategic integration of the structural heart disease business and the cardiac rhythm management ("CRM") business. By comprehensively integrating the product lines and global channel resources of both parties, the Group has made a strong entry into the strategic high ground of heart failure. We are building a comprehensive management solution covering "all causes, all stages, and the entire process" of heart failure, providing complete services for the entire cycle of "monitoring-diagnosis-treatment-management", aiming to create a world-leading heart failure diagnosis and treatment platform and comprehensively enhancing overall competitiveness in the field of cardiovascular devices.

Innovation capability remains the core driving force behind the Group's development. During the Reporting Period, we achieved fruitful results in research and development innovation, regulatory recognition, and frontier exploration, further consolidating our industry leadership:

- Innovative strength highly recognized by domestic and international regulatory authorities. During the Reporting Period and up to the date of this announcement, Hector® Thoracic Branch Stent Graft System and APOLLO Dream® Intracranial Sirolimus Target Eluting Stent System successively received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), demonstrating their potential to address unmet clinical needs. In China, the Group had 8 additional products admitted to the "Green Path" for innovative medical devices, bringing the total number of products in the "Green Path" to 44, ranking first among domestic medical device companies for eleven consecutive years.

- Milestone breakthroughs in frontier technology fields. Relying on the self-developed MicroGenius® multi-modal autonomous surgical large model, the Group successfully completed the world's first animal experiment of "Large Model Autonomous Surgery," marking substantive progress in the autonomous surgical technical path for soft tissue surgical robots. Meanwhile, the Einstein® Targeted Deep Brain Stimulation System entered the pre-market clinical study enrollment stage, marking a key step of the Group in the fields of high-end neuromodulation and brain-computer interfaces.

- Significant achievements in global access for innovative products. During the Reporting Period and as of 27 March 2026, the Group saw the launch of several heavyweight products in both domestic and overseas markets. In China, a total of 36 initial NMPA Class III medical device registration certificates were obtained, including the TomaHawk® Coronary Intravascular Lithotripsy (IVL) Catheter System, YINI® Phacoemulsification System, and UniPath® Electrolaryngoscope Surgical Navigation System. Overseas, 407 initial registration certificates were obtained in 53 markets, among which the world's first MRI-compatible hybrid pacing system supporting left bundle branch pacing and the IceMagic® Cryoablation System successively obtained access to core markets, marking the continuous enhancement of the Group's international R&D and registration capabilities.

- Top-tier evidence-based medicine recognized by the global academic community. During the Reporting Period, the TARGET-FIRST clinical study of the Group's self-developed Firehawk® Coronary Sirolimus Target Eluting Stent System achieved significant results. The results were officially released at the 2025 European Society of Cardiology (ESC 2025) Congress and published in the New England Journal of Medicine ("**NEJM**"), the foremost of the "Big Four" medical journals. This study was also hailed as a "milestone" breakthrough by the European Heart Journal, a leading journal in the global cardiovascular field, and was honored as one of the "Top Ten Influential Papers" of 2025 in the field. This marks that the Group's original research and clinical evidence in the field of cardiovascular intervention have once again gained extensive recognition from the world's top academic circles, demonstrating the R&D strength and global leadership of "Intelligent Manufacturing in China".

Facing continuous challenges, leveraging the business cluster advantages accumulated over years, independent and controllable innovation capabilities, and an efficient global matrix layout, the Group will continue to deepen lean management and promote the steady development of its businesses.

Note: include the numbers of equity-accounted investees of the Group.

Cardiovascular Devices Business

As the industry evolves toward precision and complexity, the value of "Total Solutions" is accelerating its release. Currently, the global cardiovascular devices market is continuously optimizing its structure, driven by persistent clinical needs and innovations in precise and complex treatment technologies. The increasing popularity of intravascular imaging and functional examination, along with the rising demand for pre-treatment of complex lesions such as moderate-to-severe calcification, is pushing surgical strategies and devices toward a more advanced level. In China, the deepening of centralized VBP continues to guide the market to focus on innovative products with genuine clinical value. As one of the companies with the most complete coronary product lines globally, the Group's "Total Solutions" built around coronary heart disease have entered a period of intensive harvest, which not only drives an optimization of the revenue structure but also achieves a fundamental improvement in profitability. During the Reporting Period, the Group's cardiovascular devices business recorded global revenue of US$182.2 million, representing a year-on-year increase of 11.1% (excluding the foreign exchange impact). Following the successive global commercialization of several blockbuster innovative products, the growth drivers of the related businesses have been effectively transitioned. With adjusted net profit margins exceeding 20% for two consecutive years, the business has entered a steady, sustainable, and healthy growth trajectory.

- **In China, cornerstone products demonstrated resilience, while new products synergistically drove accelerated growth.** During the Reporting Period, the domestic business achieved high-quality development through excellent product iteration and operational efficiency, recording revenue of US$142.1 million (excluding the foreign exchange impact), representing a year-on-year increase of 18.9% (excluding the foreign exchange impact). As the segment's bedrock, the stent business achieved contra-trend growth in the VBP environment, with gross margin significantly increasing by 7 percentage points through strategic product portfolio layout and lean supply chain management. Meanwhile, the segment's revenue moved toward accelerated diversification: (i) sales of balloon and access devices products increased by 52% and 30% respectively year-on-year (both excluding the foreign exchange impact), and the FireFalcon® Scoring Balloon successfully won the bid in the Zhejiang provincial medical institution group procurement, enhancing its competitiveness in the domestic market; (ii) revenue from the "intervention without implantation" product line increased by 120% (excluding the foreign exchange impact) year-on-year, with the Firelimus® Drug-Coated Balloon winning the bid in the sixth round of National VBP at a mid-to-high price, achieving coverage of nearly 1,000 hospitals; and (iii) sales of active devices (excluding images) achieved a breakthrough from zero to one, contributing revenue of US$1.9 million during the Reporting Period, marking the official commencement of a new "passive + active" dual-drive growth model for this business. Through supply chain integration, lean production, and various cost-reduction measures, the operational efficiency of the segment improved, with the overall gross margin improving by 4 percentage points year-on-year and the profit structure continuously optimizing.

- **Innovative R&D and academic status continued to be consolidated.** During the Reporting Period, the evidence-based medical results of the self-developed Firehawk® Rapamycin Target Eluting Coronary Stent System were published in the top international medical journal, the NEJM, marking the highest level of recognition for its clinical value within the international academic community. The Group continued to refine its total medical solutions for coronary heart disease. As of the date of this announcement, the Group's self-developed FireSweeper® Thrombus Aspiration Catheter, FireSpear™ Piezoelectric Intravascular Ultrasound Therapeutic Equipment, and FireFeeler® FireSpear™ Disposable Intravascular Ultrasound Guidewire have successively obtained National Medical Products Administration ("**NMPA**") approval for marketing. In addition, the Coronary Sinus Balloon Counterpulsation System, as the fifth product in this segment to enter the "Green Path" for innovative medical devices, has completed enrollment for its FIM study and is expected to provide a brand-new treatment solution for patients with ST-segment elevation myocardial infarction.

- **Overseas, actively responding to short-term fluctuations while solidifying long-term foundations.** Affected by spot disturbances such as geopolitical conflicts and the fluctuation of healthcare services system, the overseas revenue of this business segment decreased by 10.1% (excluding the foreign exchange impact) during the Reporting Period. The Group actively responded to multiple challenges and seized structural opportunities: focusing on high-potential areas, achieving a year-on-year increase of 21% (excluding the foreign exchange impact) in sales revenue from the balloon product line, which became a key performance growth point; achieving key breakthroughs in core markets, with the coronary stent market share climbing – ranking first in the market – by winning large-scale bids in Istanbul and the State Supply Office in Turkey; meanwhile, successfully completing product iterations and upgrades in many parts of the world, driving an improvement in revenue quality. During the Reporting Period, global brand influence continued to strengthen through top academic conferences, with several important academic releases at industry conferences such as TCT, ESC, and EuroPCR providing vital global clinical evidence. As of the end of the Reporting Period, the Group has achieved comprehensive gradient coverage of its stent and balloon product portfolio in Europe, the Middle East, and Africa ("EMEA"), Latin America, and the Asia-Pacific region (excluding China), and is actively promoting the introduction of new products to continuously refine the global layout of the total coronary PCI solution, enhancing overall brand influence and market competitiveness.

- **Leading global precision intervention and releasing the value of total solutions.** Looking forward, the Group will continue to leverage its world-leading and complete product line layout covering pre-operative, intra-operative, and post-operative PCI procedures. By deeply integrating the synergistic advantages of R&D, manufacturing, and commercialization, the Group will accelerate the global value release of "Total Solutions" while consolidating and expanding its leading position in the Chinese market, striving to become an innovation leader and the preferred partner in the field of global interventional treatment for cardiovascular diseases.

Orthopedics Devices Business

The orthopaedic devices business provides comprehensive orthopaedic solutions, with products covering joint reconstruction, spine, trauma, and other specialized implants and tools. During the Reporting Period, this business recorded global revenue of US$235.2 million. To proactively respond to the new market landscape following the full implementation of centralized VBP for artificial joints in China, the Group firmly executed the strategic shift of "import substitution with domestic products" and carried out corresponding business structure adjustments. Affected by this strategic adjustment and the transition in VBP pricing, revenue during the Reporting Period faced short-term pressure. Meanwhile, by continuously optimizing its product structure, deepening cost reduction and efficiency enhancement, and accelerating the global launch of innovative solutions, the Group successfully increased its gross margin by 4 percentage points during the Reporting Period. The operational fundamentals have been consolidated, accumulating momentum for future high-quality development.

- **In the international market, the business demonstrated resilience in a complex environment.** During the Reporting Period, geopolitical conflicts and global supply chain fluctuations brought challenges. The international (non-China) orthopaedic business recorded revenue of US$216.6 million, representing a year-on-year decrease of 1.6% (excluding the foreign exchange impact). To consolidate long-term competitiveness, the Group continued to promote integrated solutions driven by intelligent technology. By deepening the synergistic application of the SkyWalker® Orthopaedic Surgical Robot System and the Evolution® Medial-Pivot Total Knee System, the Group provides global surgeons with more precise and efficient personalized surgical options to enhance clinical value and customer stickiness. Regarding new product progress, the NEXUS® Femoral Stem, which focuses on operational consistency and long-term stability, obtained FDA marketing clearance in the U.S. and has commenced market promotion with positive initial feedback. Meanwhile, the Evolution® Revision Knee System for complex revision surgeries, after obtaining market access in the U.S. and Canada, will also initiate market launch, which is expected to further enhance the Company's comprehensive solution capabilities in high-difficulty treatment fields.

- **In the Chinese market, the business firmly transformed amidst deep adjustments, accumulating momentum for long-term development.** With the full implementation of the second round of National VBP for artificial joints during the Reporting Period, the industry has entered a new stage guided by clinical value. The Group proactively made strategic adjustments, shifting its development focus toward domestic product lines. Affected by this structural adjustment and VBP pricing, the Chinese business recorded revenue of US$18.6 million during the Reporting Period, a year-on-year decrease of 45.4% (excluding the foreign exchange impact). During this process, the Group persisted in innovation and continuously expanded product boundaries: the localized Evolution® MPX™ Medial-Pivot Total Knee System has successively obtained U.S. FDA, Thailand, and EU CE MDR certifications, aiming to optimize the global product supply system. Furthermore, in March 2026, the Group successfully obtained NMPA marketing approval for the Cloudrider™ Shoulder Replacement System, which marked a breakthrough in the boundaries of the field of hip or knee, officially achieving core product layout in the new track of shoulder joint treatment.

- **The industry is undergoing profound changes, with intelligent transformation and efficiency innovation becoming key.** Currently, the global orthopaedic market is evolving toward precision and intelligence, with robot-assisted joint replacement and personalized solutions increasingly becoming mainstream. In China, the aging population provides long-term demand support, while the deepening of National VBP is driving the optimization of the market landscape, placing higher requirements on companies' clinical value and operational efficiency. The Group's orthopaedic business will consolidate its international business resilience while building future-oriented long-term competitive advantages in China's new cycle by continuously promoting globalized robotic intelligent integrated solutions, accelerating the launch of high-end innovative products, and firmly executing structural transformation in the Chinese market.

Heart Failure Integrated Management Business

Strategic integration builds a platform, initiating a new stage of heart failure integrated management. During the Reporting Period, the Group completed the strategic restructuring of its structural heart disease business and CRM business, marking the official entry of the Group into a new stage of deep integration and synergy-driven development. This integration aims to deeply merge the core capabilities of both parties – namely, the leading innovation of the structural heart disease business in valve biomaterials and structural design, and the profound accumulation of the cardiac rhythm management business in active implantation, precision algorithms, and data insights – to construct a comprehensive device management platform covering "all causes, all stages, and the entire process" of heart failure. Synergistic effects are expected to be released across multiple dimensions such as business expansion, operational efficiency improvement, and supply chain integration, marking the strategic upgrade of the Group in the field of diversified cardiovascular devices from providing single products to providing platform-based and integrated solutions.

Based on the aforementioned integration, making a full-scale entry into the field of heart failure treatment has become our clear strategic focus. Heart failure is the terminal stage of many cardiac diseases, with huge and unmet patient needs. Traditional treatment methods are fragmented, and our goal is to build a complete solution throughout the entire cycle of "monitoring-diagnosis-treatment-management" through the merged platform. After the integration, we will be able to provide integrated and personalized device treatment and management solutions for patients with different etiologies (such as arrhythmia and valvular disease) and various disease stages (from early to terminal stage). Currently, the layout of relevant heart failure pipelines is progressing rapidly, and the synergistic momentum brought by the merger will greatly accelerate the realization of this strategic blueprint.

Looking back at the Reporting Period, the two businesses operated as independent segments before the integration, laying a solid foundation amidst challenges and planning for the future through innovation.

– **The structural heart disease business moved forward amidst globalization breakthroughs.** During the Reporting Period, this business recorded revenue of US$51.3 million, a year-on-year increase of 1.3% (excluding the foreign exchange impact). However, business losses widened, primarily due to multiple factors including product price adjustments under the domestic VBP environment. In overseas markets, the globalization process achieved a leapfrog breakthrough, with revenue increasing by 255.0% (excluding the foreign exchange impact). The TAVI product line successfully entered multiple markets including Portugal, South Korea, Brazil, and India, with nearly 900 overseas implantations for the full year, a year-on-year increase of nearly 350%. Crucially, after obtaining the EU CE certification, the AnchorMan® Left Atrial Appendage (LAA) Closure System achieved its first implantations in Germany, Poland, and other regions, marking its official entry onto the global competitive stage. In the domestic market, the business demonstrated resilience amidst industry transformation. The Left Atrial Appendage Closure (LAAC) business showed explosive growth, with AnchorMan® achieving nearly 1,000 commercial implantations in its second year of launch, a year-on-year increase of nearly 360%, rapidly growing into a solid second growth curve for the Company. The TAVI series recorded a significant milestone of over 4,000 domestic implantations for the full year, further consolidating its leading market position with continuously deepening coverage.

– **The cardiac rhythm management business accumulated momentum during the industry cycle, driving long-term development through high-end innovation.** During the Reporting Period, this business recorded global revenue of US$229.7 million, remaining flat year-on-year. Among this, the international (non-China) business recorded revenue of US$207.0 million, a year-on-year increase of 0.7% (excluding the foreign exchange impact). The Group focuses on the cutting-edge Left Bundle Branch Area Pacing (LBBAP) technology and is committed to providing complete solutions. During the Reporting Period, the FLEXIGO™ 3D Delivery System specially developed for LBBAP successively obtained approvals from the U.S. FDA and EU CE. The supporting VEGA™ M Pacing Lead also obtained certification and completed its first implantations in Australia and several European countries, marking a comprehensive acceleration of our deployments in this field. In the Chinese market, the business was affected by the policy cycle transition of VBP in the short term, recording revenue of US$22.7 million. Significant achievements were made in high-end breakthroughs and market access: in the Guangdong Alliance renewal procurement, new products including the TEN™ series, the first domestic 3.0T whole-body MRI-compatible pacemaker, successfully won the bid. PLATINIUM™, the first NMPA-approved domestic Implantable Cardioverter Defibrillator (ICD), was officially launched, achieving a milestone breakthrough in this high-end field and further consolidating the Company's leadership in the field of cardiac rhythm.

- **Industry Transformation, Integration and Innovation Shaping the Future.** The global structural heart disease and cardiac rhythm management markets continue to develop, driven by breakthroughs in evidence-based medicine, innovations in treatment concepts, and technological advancements. In China, the normalization of VBP is driving the industry toward a new stage centered on clinical value. Companies with genuine innovative products and excellent operational efficiency will gain long-term advantages. Simultaneously, leading domestic companies are accelerating their globalization process leveraging their innovative strength. Through the aforementioned strategic integration, the Group has formed a unique platform for diversified cardiovascular device solutions. Looking forward, we will not only be committed to consolidating our existing advantages in fields such as TAVI, LAAC, pacing, and defibrillation but will also fully utilize platform synergies to make a full-scale entry into the vast "blue ocean" market of heart failure. We aim to provide global patients with full-cycle solutions from disease monitoring and diagnosis to treatment and management, opening a new chapter of sustainable growth.

Endovascular and Peripheral Vascular Devices Business

The aortic and peripheral vascular interventional business ("MicroPort Endovastec") focuses on providing integrated disease solutions for aortic, peripheral vascular, and oncological diseases. During the Reporting Period, MicroPort Endovastec recorded revenue of US$189.5 million, representing a year-on-year increase of 12.0% (excluding the foreign exchange impact). Through the continuous volume expansion of core products, the contribution of high-growth new products, and the economies of scale from overseas business, the net profit reached US$77.7 million, representing a year-on-year increase of 12.2%, demonstrating high-quality growth resilience in a complex market environment.

- **In China, deepening market penetration and product innovation to consolidate the leading domestic position.** During the Reporting Period, revenue from the China business achieved steady growth. In the field of aortic intervention, the Company actively promoted market down-streaming and the diversification of treatment solutions, with the market share of core products increasing steadily. Among them, the Castor® Branched Aortic Stent Graft and Delivery System has cumulatively covered over 1,400 end-user hospitals; Minos® Abdominal Aortic Stent Graft and Delivery System has cumulatively covered nearly 1,200 end-user hospitals; and Reewarm® PTX Drug-coated Balloon Catheter has cumulatively covered nearly 1,400 end-user hospitals. The Talos® Thoracic Stent Graft System achieved a rapid increase in implantation volume due to its superior clinical effects; the implantation volumes of the Castor® Branched Stent Graft System and Minos® Abdominal Aortic Stent Graft System also maintained high-speed growth. In the field of peripheral vascular intervention, the Reewarm® PTX Drug-Coated Balloon accelerated its volume expansion following the implementation of VBP policies. The distribution network continued to deepen. As of the end of the Reporting Period, products have cumulatively covered nearly 2,900 hospitals in China, laying a solid foundation for long-term growth. Significant progress was made in new products and the R&D pipeline: the new generation Cratos® Branched Aortic Stent Graft System was quickly applied clinically after its launch; the Tipspear® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Puncture Set and FinderSphere® PVA Embolization Microspheres successively obtained NMPA approval, marking substantive progress in the field of oncology intervention. Furthermore, the Hector® Thoracic Multi-branch Stent Graft System for treating complex aortic diseases has entered the National Green Path for innovative medical devices and is in the pre-market clinical stage; the Aegis® II Abdominal Aortic Stent Graft System has completed the submission of registration materials. Multiple R&D products for peripheral arterial, venous, and oncology interventions are progressing as planned, reserving sufficient momentum for the future.

- **Overseas, globalization has become a core growth engine, with high-end innovation receiving international authoritative recognition.** During the Reporting Period, sales revenue from overseas business increased by 56.5% year-on-year (excluding the foreign exchange impact), with its proportion of total revenue rising to 19%, showing strong growth momentum. The globalization network expanded rapidly, with 7 new countries or regions added during the year, and products have cumulatively entered nearly 50 markets worldwide. Fruitful results were achieved in international access. As of the end of the Reporting Period, the Company had obtained initial registration certificates for 11 products in 29 overseas markets, with a cumulative total of over 110 overseas product registration certificates, of which 6 obtaining CE certification and 3 products receiving EU custom-made device certificates. Core products such as Castor® and Minos® have entered approximately 30 countries or regions; innovative products such as Cratos® and Talos® also successfully achieved overseas sales. Crucially, the Hector® Thoracic Multi-branch Stent Graft System received the Breakthrough Device Designation from FDA in March 2026, which not only validates the product's huge potential to address unmet clinical needs but also provides an accelerated path for its subsequent clinical and registration processes in the U.S. market, marking an important milestone in the Company's innovation strength being recognized by the world's top markets.

- **Accelerated restructuring of industry landscape, with globalization opportunities becoming increasingly prominent.** Currently, the global aortic and peripheral vascular interventional market maintains continuous growth driven by population aging and increased health awareness. In China, the market penetration of aortic intervention is still deepening; in the peripheral arterial field, products such as drug-coated balloons and atherectomy are becoming increasingly widely used under the promotion of concepts like "intervention without implantation"; the demand for peripheral venous disease treatment and the primary care market is accelerating its release. Domestic manufacturers, with excellent cost-performance ratios and innovative iteration capabilities, are double beneficiaries of import substitution and the globalization process. MicroPort Endovastec will continue to leverage its diversified innovative product matrix, deeply covered channel network, and increasing international brand influence to accelerate its pace into the global market while consolidating its leading domestic advantages, striving to become a world-leading integrated solution provider in this field.

Neuroscience Business

The industry has entered a stage of high-quality development driven by centralized VBP, bringing structural opportunities for domestic leaders. The Chinese neurovascular devices market has a solid demand foundation under the huge burden of stroke diseases and the continuous improvement of the stroke center network. With the full rollout and normalization of VBP for high-value consumables, the industry is shifting from rapid expansion to a stage of high-quality development centered on clinical value and cost-effectiveness, creating a window for integration and growth for domestic leading enterprises with full-product-line solutions. Simultaneously, with strong support from national policies, the industrialization of disruptive technologies such as brain-computer interfaces has accelerated, opening new frontiers for the industry's long-term development. Through multi-dimensional empowerment, policies are actively supporting Chinese medical device companies in their journey to go global, enabling Chinese companies achieve a leap in both technology and brand in the international

market competition. The Group's neuroscience business ("MicroPort Neuroscientific"), as the pioneer and the largest domestic brand in China's neurovascular medical device field, is committed to providing total solutions for cerebrovascular diseases covering hemorrhagic, ischemic, and stenotic fields. During the Reporting Period, the business recorded revenue of US$111.0 million, representing a year-on-year increase of 3.8% (excluding the foreign exchange impact). Facing the pricing pressure brought by VBP in the Chinese market, this business continuously optimized its cost structure through supply chain management and lean production. During the Reporting Period, the gross margin increased against the trend by 0.5 percentage points to 73.5%, demonstrating excellent operational efficiency and profitability resilience.

- **In the Chinese market, the Group consolidated and expanded its leading advantage under the VBP background with the most complete domestic product portfolio.** During the Reporting Period, products cumulatively supported over 66,700 neurointerventional surgeries, a year-on-year increase of over 30%. By extensively participating in and winning bids for multiple provincial and inter-provincial alliance VBPs, the Group successfully accelerated market down-streaming and market share enhancement. In the field of hemorrhagic stroke treatment, the implantation volume of the NUMEN® series Coils increased significantly year-on-year, and the new generation NUMEN® NEST Coils has been approved for marketing. The Tubridge® series Flow Diverter Stent accelerated hospital coverage after VBP, achieving rapid growth in implantation volume. In the field of atherosclerotic stenosis treatment, the newly added large-diameter specification product in the Bridge® series, the Bridge® MAX vertebral artery drug-eluting stent, received approval during the Reporting Period, filling the clinical gap for large-size stents of 4.5/5.0mm. It has been listed on centralized procurement platforms in 24 provinces and municipalities. In the field of acute ischemic stroke treatment, the Group focused on primary hospitals, with new generation thrombectomy and aspiration products successively approved and quickly achieving market access, providing one-stop device solutions. As of the end of the Reporting Period, the business has cumulatively covered nearly 3,800 hospitals in China, achieving full coverage of the top 100 National Advanced Stroke Centers.

- **In overseas markets, global expansion entered a new stage of profitable rapid growth and has become an important growth engine.** During the Reporting Period, overseas revenue increased by 39.4% year-on-year, with its proportion of total revenue rising to 13%, achieving continuous profitability with net profit expanding significantly by 142% year-on-year. Key breakthroughs were made in various regional markets: in the Asia-Pacific region, the Group continued to expand its market presence, achieving multiple new product approvals and hospital tenders in South Asia, while completing product registrations in several countries. The direct sales model in South Korea was fully implemented, with the NUMEN® series achieving significant growth in implant volumes, and the X-track® catheter making a key breakthrough in its medical insurance application in the country. In the EMEA region, the direct sales model in the United Kingdom operated smoothly, delivering rapid year-on-year growth. Meanwhile, multiple products were launched in several European countries during the Reporting Period, with initial expansion into emerging markets such as Turkey and Egypt, further strengthening regional competitiveness. In North America, the direct sales model operated efficiently, driving continued volume growth of the NUMEN® series following its launch, while steadily expanding brand influence. In Latin America, the NeuroHawk® intracranial thrombectomy stent and X-track® catheter received positive feedback after launch, with market

acceptance continuing to grow. As of the end of the Reporting Period, the Group had successfully brought 17 products to overseas markets, achieving commercialization in a total of 36 countries or regions outside the Chinese Mainland, covering nine of the top ten countries globally in terms of neurointerventional procedure volume. Crucially, the Group achieved a milestone breakthrough in the registration of frontier products. In March 2026, the APOLLO Dream® Intracranial Rapamycin Target Eluting Stent System was granted the "Breakthrough Device Designation" by the U.S. FDA, becoming the world's first rapid-exchange drug-eluting stent in the neurointerventional field to receive this designation. This recognition not only marks international authoritative approval of the product's innovative value in treating Intracranial Atherosclerotic Disease (ICAD) but also directly provides a key access advantage for MicroPort NeuroScientific to accelerate its entry into core global markets such as the U.S., establishing an important regulatory and clinical foundation.

- **R&D innovation and frontier layout continued to deepen.** As of the date of this announcement, The Group had a total of 28 products that have been approved and commercialized in China, with six of them admitted to the National Green Path for innovative medical devices, ranking first among domestic peers. Building on the solid foundation established in neurointervention, the Group is extending its capabilities into the frontier directions of neurosurgery and brain-computer interfaces (BCI). In the field of neurosurgery, we will provide innovative solutions for diseases such as cerebral hematoma, hydrocephalus, and brain tumors, among which the StraitPass® Disposable Hematoma Aspiration Device has entered the National Green Path for innovative medical devices. In the field of brain-computer interfaces, we focus on active rehabilitation after stroke and intervention for psychiatric diseases, and officially established the "Chaos BCI Research Institute" during the Reporting Period. This institute will rely on the Group's platform technology in neurointervention to focus on the R&D of implantable BCI devices primarily through interventional methods, conducting frontier exploration for major clinical needs such as post-stroke rehabilitation, Alzheimer's disease, and depression, aiming to cultivate long-term growth momentum for the future.

- The Group's neuroscience business will continue to rely on its most complete commercialized product matrix in China, a rapidly advancing R&D pipeline, and an increasingly mature global commercialization network. While responding to the new normal of domestic VBP, it will seize the strategic opportunity of domestic innovation going global and consolidate its long-term leadership in the fields of cerebrovascular and brain science through strategic layouts in frontier technologies such as brain-computer interfaces.

Surgical Robot Business

The industry has entered the eve of an intelligence explosion, with globalization and frontier technologies defining new heights. The global surgical robot market is growing rapidly, driven by clinical value and accelerated technology integration. The policy environment in China continues to improve, providing a framework for billing, payment, and standardized application. Simultaneously, domestic enterprises are accelerating their global expansion leveraging integrated innovations such as 5G and artificial intelligence. The Group's surgical robot business ("MicroPort MedBot"), as the only platform-oriented company in the world covering five major golden surgical specialties, is achieving simultaneous breakthroughs in domestic and overseas markets with its leading technology and commercialization capabilities. During the Reporting Period, MicroPort MedBot recorded revenue

of US$77.6 million, representing a significant year-on-year increase of 114.2% (excluding the foreign exchange impact). The growth was driven by robust global commercialization. As of the date of this announcement, cumulative orders for core products reached nearly 300 units, with nearly 200 units installed globally. Through strategic focus and lean operations, the operational quality of the segment has been significantly strengthened: the gross margin increased by 15 percentage points, the net loss narrowed by 60.7% year-on-year, and the free cash flow position improved substantially. Notably, along with the rapid increase in the installed base, revenue from supporting consumables achieved a significant growth during the Reporting Period, indicating a continuously optimized business model.

- **Global commercialization deepened extensively, leading domestic brands in overseas expansion.** During the Reporting Period, the surgical robot business achieved a milestone leap in overseas commercialization. By deepening intra-group synergy, the segment recorded overseas sales revenue of US$56.0 million during the Reporting Period, representing a significant year-on-year increase of 286.6%, becoming a core engine driving performance growth. By product, the Toumai® Laparoscopic Surgical Robotic System ("Toumai®"), as a domestic leader, signed over 100 new overseas orders for the full year, with its annual global order volume ranking among the top two worldwide, and added 80 commercial installations. As of the date of this announcement, cumulative global orders for Toumai® exceeded 220 units, covering over 50 countries and regions, with over 140 commercial installations completed, maintaining the top global position among domestic brands in both orders and installations. As of the date of this announcement, cumulative global orders for the SkyWalker® Orthopaedic Surgical Navigation Positioning System ("SkyWalker®") exceeded 65 units, with its market network covering five continents, maintaining a leading position in the global commercialization of domestic orthopaedic robots. Meanwhile, the R-ONE® Vascular Interventional Robot successfully entered six leading domestic hospitals during the Reporting Period, including Zhongshan Hospital affiliated with Fudan University. By continuously demonstrating innovative results and cutting-edge applications such as remote surgery at top international academic conferences, the brand image and clinical value of the Group's "Intelligent Manufacturing in China" have gained wide recognition worldwide, laying a solid academic and brand foundation for long-term overseas market expansion.

- **Global certification accelerated comprehensively, and the R&D pipeline continued to deliver.** During the Reporting Period, the Group achieved significant results in global registration access and R&D progress for its surgical robot products. The core product Toumai® obtained certifications from nearly 40 countries and regions during the year, with cumulative global certifications exceeding 60 countries and regions. The Toumai® Single-port Surgical Robot successively obtained China NMPA approval and UAE MOHAP registration approval during the Reporting Period and successfully entered Cleveland Clinic Abu Dhabi, building a solid foundation for commercial expansion. SkyWalker has obtained approvals from nearly 20 countries and regions, including China NMPA, U.S. FDA, and EU CE, and its "hip-and-knee compatibility" function also received CE certification during the Reporting Period, further expanding its clinical application scope. Regarding the R&D pipeline, an important breakthrough was achieved: the self-developed UniPath® (UniPath™) Electrolaryngoscope Surgical Navigation System was approved for marketing by the NMPA in December 2025. Designed around four core capabilities – "full lung reach, full-process visualization, precise alignment, and stable operation" – it significantly improves the certainty of lung nodule sampling, enhances intraoperative operational stability, reduces the risk of potential

complications, and lays a technical foundation for subsequent treatment scenarios such as precision ablation. With the successful implementation of the layout in the "natural orifice" track, MicroPort MedBot has become the first company in the world to have products approved for commercialization across all five major golden surgical tracks. The leading position and completeness of the product portfolio have been further consolidated, providing an increasingly rich product matrix for global expansion.

- **Leading with frontier technologies to define new models of remote and autonomous surgery.** During the Reporting Period, the surgical robot business achieved a series of breakthroughs in cutting-edge fields. Relying on the self-developed MicroGenius® Multi-modal Autonomous Surgical Large Model, Toumai® successfully completed the world's first animal experiment of "Large Model Autonomous Surgery", with a success rate of 88% in key steps. This marks a core leap for AI from decision support to autonomous execution, taking the lead in completing the three-stage milestone leap from industrialization and remote commercialization to breakthroughs in autonomous surgery. The self-developed Toumai® Laparoscopic Surgical Robotic System Remote Surgery All-department Application ("Toumai® Remote") obtained NMPA approval, becoming the world's first and only commercialized remote surgical platform capable of achieving "all-department and all-procedure" coverage. It has been approved for marketing in nearly 10 countries, with its application network covering regions inhabited by nearly half of the global population. The system has successfully assisted in nearly 800 remote human surgeries worldwide, covering over 20 countries, with a 100% implementation success rate. It has cumulatively created over 60 world records and realized a closed-loop for transcontinental and transoceanic remote surgery, establishing a comprehensive leading position in the global remote surgery field. In terms of communication technology, the Group pioneered the "Second-generation Remote Surgery" system compatible with 5G and conventional networks, and took the lead in realizing "Third-generation Remote Surgery" based on high- and low-orbit satellites, constructing an integrated global remote surgical network covering land, sea, air, and space.

- Looking forward, MicroPort MedBot will continue to rely on its most comprehensive global product pipeline layout, continuously breaking through frontier technologies and its deeply synergistic global network. While leading the intelligent transformation of surgery, the Company will accelerate the translation of innovative achievements into global market growth, striving to become a global leader in reshaping the future of surgical procedures.

Research and Development ("R&D")

During the Reporting Period and up to 27 March 2026, the Group had a total of 36 Class III medical devices initial registration certificates from the NMPA, and eight innovative medical devices were admitted in the Green Path, reaching a total of 44 "Green Path" innovative medical devices, ranking first in the medical device industry for ten consecutive years. The Group has established a global network for innovation, which includes overseas R&D, clinical trials, and other activities, to continuously promote the launch of its innovative products in overseas markets. In terms of overseas business, during the Reporting Period and up to 27 March 2026, the Group obtained 407 initial registration certificates in 53 overseas markets (countries and regions). The Hector® Thoracic Aortic Multi-Branch Stent Graft System and the APOLLO Dream® Intracranial Artery Sirolimus-Targeted Eluting Stent System, two innovative medical device products, successively received Breakthrough Device Designation from the U.S. FDA, once again validating the Group's global clinical translation capability.

During the Reporting Period and up to the date of this announcement, the Group received approval for NMPA initial registration and significant changes, including but not limited to: Firelimus® Coronary Rapamycin-Eluting Balloon Dilatation Catheter, TomaHawk® Coronary Intravascular Catheter, the TEN™, a domestically-produced pacemaker compatible with 3.0T whole-body MRI examinations, the Cratos® Branched Aortic Stent Graft and Delivery System, the Tipspear® Transjugular Intrahepatic Puncture Device, the Toumai® SP Abdominal Endoscopic Single-port Surgery System, the Toumai® Abdominal Endoscopic Remote Surgery System, Sheathru™ Delivery Catheter, Cerelmon™ filter extension tube for single use, NeuroHawk Medibox™ Intracranial Stent Retriever and Accessories, Numen® Nest Detachable Coil, YINI® Phacoemulsification System, YairDent® Dental Implant System, EZ-Eye™ 5100 Series Intelligent Auto-Focus Auto-Magnification Electronic Digestive Endoscopy System, TACTIC® Antarctic™ Dual-Channel Tumor Cryoablation System, and UniPath® Electronic Bronchoscope Surgical Navigation System. The marketing approval of innovative products will be the important engines of the Group's business growth.

The Group will continue to efficiently promote the expansion and marketing of its products in both domestic and overseas markets, enhance the market strategy of penetrating hospitals with product mix through the global distribution of high-value diversified products, fully leverage the advantages of "group-type" operation in order to consolidate the foundation for profitability.

Note: include the numbers of equity-accounted investees of the Group.

GloMatrix Commercialisation Platform

To empower the Group's business segments in unlocking the boundless potential of exploring global markets and to extend our commercial influence worldwide, the Group has established a comprehensive marketing and service network platform (the "GloMatrix Platform") with a grid-like coverage. In this way, we bolster the primary channels of business sub-segments by strategically addressing areas where the sub-segments find "out of reach". The GloMatrix Platform will not only shepherd our portfolio of about 250 products that has been released and the innovative marvels that will be successively approved for launch, fueling the Group's sales growth, but also promote the optimization, sharing, and coordination of resources within the Group at home and abroad by refining resource allocation, thereby comprehensively enhancing the operational efficiency of the Group.

Through years of relentless growth, our Group has ascended to the forefront as a leading enterprise of high-end medical devices, operating multiple business segments across the globe. We boast a comprehensive network of research and development, manufacturing, marketing, and service that spans across Asia, North America, Europe, Latin America, and beyond. Up to date, our innovative products have reached more than 20,000 hospitals in over 100 countries and regions. The global platform consolidates all business resources within the Group, including overseas local business resources within the system, radiating from core countries/regions to surrounding areas. Each regional platform supports the integrated sales of business sub-segments products and provides functional services such as medical services, customer operations, and regulatory compliance. The HQ going-abroad platform (the "HQ Going-abroad Platform") modeled after the commercialization team of the cardiovascular devices business under the GloMatrix Platform is crafted to empower the domestically developed products of diverse business segments, enabling swift international market entry and boosting overseas sales. During the Reporting Period, the revenue of the HQ Going-abroad Platform amounted to US$109.2 million, representing a year-on-year growth of 106.6% (excluding the foreign exchange impact).

The Group's various business segments have presented robust growth momentum in the sales of going-abroad products (the "Going-abroad Business"), leveraging both their independent overseas sales channels and the synergistic advantages of the HQ Going-abroad business. During the Reporting Period, the revenue of the HQ Going-abroad Business amounted to US$163.9 million, representing a year-on-year growth of 78.8% (excluding the foreign exchange impact). Specifically, the surgical robot business increased by 286.6% year-on-year (excluding the foreign exchange impact), the endovascular and peripheral vascular devices business increased by 56.5% (excluding the foreign exchange impact), the neuroscience devices business increased by 39.4% year-on-year (excluding the foreign exchange impact), and the structural heart disease business increased by 255.0% (excluding the foreign exchange impact).

Moving forward, the Group's business segments will continue to leverage the GloMatrix Platform's integrated distribution network to efficiently deliver innovative products and expand into untapped international markets, thereby strengthening the global competitiveness of the Group.

HUMAN RESOURCES AND TRAINING

As at 31 December 2025, the Group had a total of 6,547 employees around the world, of which 1,722 or approximately 26% were overseas employees in the Asia Pacific region, Europe, the Middle East, Africa, North America, South America and Australia.

To cope with the increasing uncertainty in the external market, the Group is committed to building a flexible and resilient organizational competence system. By reviewing the key work of various business segments within the Group and checking the distribution of human resources, the Group has further deepened its internal collaboration mechanisms, continuously expanded the functional coverage and operational depth of its platform-based shared services, and promoted an increase in overall synergy. In this process, the Group will make overall arrangements for relevant projects and positions in line with its global strategy and solidify the foundation for global organizational synergy, thereby achieving coordinated and enhanced organizational efficiency. The Group is committed to providing employees with more diverse development opportunities by building a global organizational competence system, integrating resources and empowering platforms as well as upgrading management and operation methods. The Group provides its global employees with ample space for career development that combines horizontal and vertical dimensions by continuously adhering to the principle of "maturity, usage, remuneration, cultivation and care" regarding human resources, and helps talents accelerate their development and pursue the realization of self-worth through internal four institutes (Earth-Down Leadership Academy (稷下企業領導力學院), MicroPort Innovation Action Academy (微創創新知行學院), Innovation Qualification & Competency Institute (創新資質與能力學堂), and Culture & Philosophy Academy (文化&哲學講堂) within the enterprise, so as to work together to achieve its belief of "helping hundreds of millions of earthlings to have a lifespan of over 115 years old in a healthy manner".

PROSPECTS

In the long run, with the deepening of population ageing in the world, the improved living standards of the people and the economic growth of the developing countries, it is anticipated that the global market demand for medical devices will also steadily increase. As for the PRC market, thanks to the economic and social development, the health awareness among its people has been raised significantly, and the reform of the medical system has also brought policy bonuses. The medical device market in China has huge development opportunities.

In the short term, the global economy is still subject to macro-economic factors such as the uncertainty of the development trend, the tightening of trade protection policies and the intensification of geopolitical conflicts. On the industry side, competition in the domestic medical device sector continues to intensify. Centralized VBP of high-value medical consumables, reforms in medical insurance payments, and measures for refined management of medical expenses, such as pharmaceutical price control, are continuously being advanced, leading to an impending adjustment in the industry's landscape. The above factors will all increase uncertainty and may have an adverse impact on the Group's operations and the value of its related business segments.

In order to seize the development opportunities and enhance our core competitiveness in the increasingly fierce market competition, we will continue to implement positive business strategies, strictly adhering to the strategies of focusing on principal business and cost control, and proactively manage and hedge any potential risks, with actions as follows:

1. Consolidating our leading position in the medical device market in the PRC. With our strong brand recognition, extensive distribution network, and the economies of scale achieved by the deployment of multiple channels, we will further increase our market share in the PRC and continue to give full play to the advantages of being a leading enterprise in the industry and make all-round breakthroughs in the domestic high-end medical device industry, thereby maximising value for the shareholders, customers, employees and society.

2. Expediting the global expansion to realize integration of MicroPort® brand and global operations. We will continuously deepen the globalized branding and operation strategy based on localization by consistently implementing the operation model of "globalization in operational strategy, localized implementation, deployment with diversification, and unified positioning", thereby realising global deployment through effective integration of resources and markets around the world, which in turn will bring the products of MicroPort® to more countries or regions and benefit patients and doctors around the world.

3. Constantly refining our existing production processes, and carrying out innovation to gain high returns so as to create a diversified product portfolio. We will continuously optimize the manufacturing processes of existing products to enhance their production efficiency; and pay more attention to the input-output ratio of research and development from the perspective of enterprise strategy, committing ourselves to providing more high-quality and affordable integrated medical solutions for doctors and patients while improving profitability.

4. Deepening the reform of our management system. In order to further enhance the competitiveness and risk prevention capability of the Company, we will constantly improve the system development and enhance the efficiency of internal governance by integrating resources and streamlining processes, thereby maintaining the unique entrepreneurial vitality, flexibility and efficiency of MicroPort® to the greatest extent while rapidly expanding the scale of the Company.

FINANCIAL REVIEW

Overview

Despite facing the impact of complex and changing unfavorable factors in China and abroad, the revenue of the Group during the Reporting Period increased by 6.0% excluding the foreign exchange impact or increased by 7.2% in US$ as compared to the year ended 31 December 2024. The Group persisted in continuously providing a diversified product portfolio and continuously carrying out its globalization strategy, with non-China sales contributing to 53.1% of the total revenue. The Group aimed to continuously bring its innovations, technologies and services to millions of global patients and become a patient-oriented global leading enterprise in high-tech medical segments represented by minimal invasive treatment and other emerging medical markets.

The following discussion is based on, and should be read in conjunction with, the financial information and the notes thereto included elsewhere in this announcement.

Revenue

US$'000	**Year ended 31 December**		**Percentage change**	
	2025	2024 (Re-presented) *(Note)*	in US$	excluding the foreign exchange impact
Continuing operations				
Cardiovascular devices business	**182,181**	165,735	9.9%	11.1%
Orthopedics devices business	**235,155**	252,706	(6.9%)	(7.5%)
CRM business	**229,719**	220,613	4.1%	0.0%
Endovascular and peripheral vascular devices business	**189,481**	169,537	11.8%	12.0%
Structural heart disease business	**51,314**	50,697	1.2%	1.3%
Surgical robot business	**77,575**	36,022	115.4%	114.2%
Other business *	**95,609**	51,724	84.8%	88.9%
Elimination adjustments	**(66,689)**	(22,952)	190.6%	233.9%
Discontinued operation				
Neuroscience business	**111,036**	106,981	3.8%	3.8%
Total	**1,105,381**	1,031,063	7.2%	6.0%
Including: the HQ Going-abroad Platform	**109,248**	56,324	94.0%	106.6%

Note: The comparative information of segment revenue has been re-presented to reflect the changes in allocation of resources and assessment of performance

* The revenue of other business segments did not meet the quantitative thresholds for determining reportable segments.

The Group's revenue during the Reporting Period was US$1,105.4 million, representing an increase of 7.2% as compared to US$1,031.1 million for the year ended 31 December 2024. The Group's reported revenue was impacted by the appreciation or depreciation of US dollars against functional currencies in the process of converting from non-dollar functional currencies of the Group's subsidiaries to US dollars, the presentation currency of the Group. Excluding the foreign exchange impact, the Group's revenue increased by 6.0%. Such increase was mainly attributable to the rapid market penetration and the revenue contribution from new products. The following discussion was made based on the Group's major business segments.

– *Cardiovascular devices business*

The cardiovascular devices business recorded revenue of US$182.2 million during the Reporting Period, representing an increase of 11.1% excluding the foreign exchange impact or an increase of 9.9% in US$ as compared to the year ended 31 December 2024. Such increase in revenue was primarily attributable to the continued leading market share of domestic stent products, coupled with the rapid revenue growth from balloons, accessories, and active products. In contrast, the international coronary business faced short-term macroeconomic challenges in certain regions, including shifting geopolitical dynamics and fluctuations in healthcare service systems, which had a temporary impact on revenue.

– *Orthopedics devices business*

US$'000	**Year ended 31 December**		**Percentage change**	
	2025	2024	in US$	excluding the foreign exchange impact
Orthopedics devices business	**235,155**	252,706	(6.9%)	(7.5%)
－US	**73,640**	84,196	(12.5%)	(12.5%)
－Europe, Middle East and Africa	**83,054**	81,785	1.6%	(1.1%)
－Japan	**31,488**	29,381	7.2%	6.2%
－The PRC	**18,567**	34,071	(45.5%)	(45.4%)
－Others	**28,406**	23,273	22.1%	26.7%

The orthopedics devices segment recorded revenue of US$235.2 million during the Reporting Period, representing a decrease of 7.5% excluding the foreign exchange impact or a decrease of 6.9% in US$ as compared to the year ended 31 December 2024. Such decrease in revenue was primarily due to supply chain fluctuations, changes in the geopolitical landscape and the strategic shift of "import substitution with domestic products" in the Chinese market, which had a temporary impact on revenue.

– *CRM business*

US$'000	**Year ended 31 December**		**Percentage change**	
	2025	2024	in US$	excluding the foreign exchange impact
CRM business	**229,719**	220,613	4.1%	0.0%
－Europe, Middle East and Africa	**190,836**	181,586	5.1%	0.2%
－The PRC	**22,749**	24,269	(6.3%)	(6.1%)
－Japan	**9,427**	8,718	8.1%	6.6%
－Others	**6,707**	6,040	11.0%	8.6%

The CRM business recorded revenue of US$229.7 million during the Reporting Period, which was relatively flat (excluding the foreign exchange impact) or an increase of 4.1% in US$ as compared to the year ended 31 December 2024. Such change in revenue was mainly attributable to (i) the wide recognition of the next-generation pacemakers and defibrillators with Bluetooth connectivity and MRI compatibility by clinicians and patients globally since launch; and (ii) the decline in revenue from the CRM business in China by 6.1% year-on-year excluding the foreign exchange impact as a result of the later-than-expected rollout of VBP initiatives during the Reporting Period.

– *Endovascular and peripheral vascular devices business*

The endovascular and peripheral vascular devices business recorded revenue of US$189.5 million during the Reporting Period, representing an increase of 12.0% excluding the foreign exchange impact or an increase of 11.8% in US$ as compared to the year ended 31 December 2024. Such increase in revenue was mainly attributable to the following factors: (i) during the Reporting Period, innovative products continued to solidify the domestic leading advantage. By deeply cultivating the lower-tier markets, offering customised treatment solutions, accelerating product upgrades and iterations, and actively promoting the launch of new products while replacing older ones, the market share has achieved steady growth; and (ii) our overseas markets achieved a rapid year-on-year growth of 56.5% (excluding the foreign exchange impact), driven by its deepening global presence and the continued expansion of market access and promotional activities for our aortic and peripheral interventional products in regions including Europe, Latin America, and the Asia-Pacific.

– *Structural heart disease business*

The structural heart disease business recorded revenue of US$51.3 million during the Reporting Period, representing an increase of 1.3% excluding the foreign exchange impact or an increase of 1.2% in US$ as compared to the year ended 31 December 2024. Such increase in revenue was mainly attributable to the rapid growth in the overseas revenue of this business by 255.0% (excluding the foreign exchange impact) comparing with the corresponding period in 2024, contributed by the continued advancement of the VitaFlow Liberty® and the Alwide® Plus in terms of global commercialization, contributing additional revenue to the Group.

– *Surgical robot business*

The surgical robot business recorded revenue of US$77.6 million during the Reporting Period, representing an increase of 114.2% excluding the foreign exchange impact or an increase of 115.4% in US$ as compared to the year ended 31 December 2024. Such increase was primarily attributable to the breakthrough commercial progress of Toumai, resulting in a sharp sales growth. In particular, the remarkable expansion in overseas markets has made the international segment a key growth driver for revenue growth.

– *Other business*

The Group's other business recorded revenue of US$95.6 million during the Reporting Period, representing an increase of 88.9% excluding the foreign exchange impact or an increase of 84.8% in US$ as compared to the year ended 31 December 2024. Such increase was mainly attributable to the increase of revenue from non-vascular intervention and other emerging business segments. The revenue of other business did not meet the quantitative thresholds for determining reportable segments.

– *Neuroscience business*

The neuroscience business recorded revenue of US$111.0 million during the Reporting Period, representing an increase of 3.8% (excluding the foreign exchange impact or in USD terms) as compared to the year ended 31 December 2024. Such increase in revenue was mainly attributable to the following factors: (i) the continued growth of the business's overseas operations, with revenue increasing by 39.4% year-on-year (excluding the foreign exchange impact) during the Reporting Period, with strong sales growth across the Asia-Pacific, North America, Latin America, and Europe, Middle East, and Africa regions to varying degrees; (ii) in the field of hemorrhagic stroke products, revenue from coil series products maintained rapid growth, resulting in a further expansion of the market share, and the revenue from Flow-diverting Stent decreased due to the impact of the VBP.

Cost of Sales

During the Reporting Period, the Group's cost of sales was US$470.8 million, representing an increase of 3.0% as compared to US$457.0 million for the year ended 31 December 2024. Such increase was driven by increased sales volume.

Gross Profit and Gross Profit Margin

As a result of the foregoing factors, the Group's gross profit increased by 10.5% from US$574.1 million for the year ended 31 December 2024 to US$634.6 million during the Reporting Period. Gross profit margin is calculated as gross profit divided by revenue. The Group's gross profit margin during the Reporting Period increased by 57.4% as compared to a gross profit margin of 55.7% for the year ended 31 December 2024, which was mainly attributable to the supply chain integration and process optimization.

Research and Development Costs

Research and development costs decreased by 32.3% from US$216.5 million for the year ended 31 December 2024 to US$146.5 million during the Reporting Period. Such significant decrease resulted from the proactive cost control and resource focus measures taken by the Group to prioritize and focus on core projects and improve R&D efficiency.

Distribution Costs

Distribution costs increased by 4.6% from US$304.2 million for the year ended 31 December 2024 to US$318.1 million during the Reporting Period. Such increase was mainly attributable to the expansion in major business markets, product promotion activities, and the corresponding rise in sales commissions in line with revenue growth.

Administrative Expenses

Administrative expenses decreased by 4.0% from US$176.6 million for the year ended 31 December 2024 to US$169.6 million during the Reporting Period. Such decrease primarily resulted from the Group's strategic realignment of global resource allocation, executing targeted corporate streamlining and cost-discipline initiatives that enhanced operational efficiency.

Other Net Income

The Group recorded other net income of US$55.0 million during the Reporting Period and other net loss of US$29.4 million for the year ended 31 December 2024. Such increase was mainly attributable to the exchange gains and the increase in government grants recognised during the Reporting Period.

Finance Costs

Finance costs increased by 4.8% from US$106.4 million for the year ended 31 December 2024 to US$111.5 million during the Reporting Period. Such increase was mainly attributable to the increase in accrued interest of the convertible bonds issued by the Company.

Impairment Losses of Non-current Assets

Impairment losses of non-current assets increased by 22.1% from US$87.9 million for the year ended 31 December 2024 to US$107.3 million during the Reporting Period. Such change was mainly attributable to the increase in impairment provisions for equity-accounted investees during the Reporting Period.

Income Tax

Income tax decreased from US$43.7 million for the year ended 31 December 2024 to US$38.0 million during the Reporting Period. Such change was primarily attributable to certain one-off tax items recorded in the previous year, which did not occur in the Reporting Period.

Profit/(loss) for the Year

The Group turned profitable during the Reporting Period, improving from a loss of US$268.5 million last year to a profit of US$38.4 million during the Reporting Period. The Group's EBITDA[#] increased significantly from US$60.4 million for the year ended 31 December 2024 to US$369.8 million during the Reporting Period.

Non-HKFRS Measures

To supplement our consolidated statements of profit or loss which are presented in accordance with HKFRS Accounting Standards, we also use adjusted net loss as non-HKFRS measures, which are not required by, or presented in accordance with, HKFRSs Accounting Standards. We believe that the presentation of non-HKFRS measures when shown in conjunction with the corresponding HKFRS Accounting Standards measures facilitates a comparison of our operating performance from period to period by eliminating potential impacts of items that the management does not consider to be indicative of our operating performance. Such non-HKFRS measures allow investors to consider metrics used by our management in evaluating our performance.

From time to time in the future, we may exclude other items from our review of financial results. The use of the non-HKFRS measures has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for or superior to analysis of, our results of operations or financial condition as reported under HKFRS Accounting Standards. In addition, the non-HKFRS financial measures may be defined differently from similar terms used by other companies and therefore may not be comparable to similar measures presented by other companies.

This refers to earnings before interest, taxes, depreciation and amortization, which includes changes in fair value of convertible bonds issued by a subsidiary recognised in profit or loss during the year.

The following table sets out the reconciliation to net loss for the periods indicated:

	Year ended 31 December		
	2025	2024	**Change**
	US$'000	*US$'000*	*%*
Profit/(loss) for the Year	**38,427**	(268,459)	(114.3%)
Add/(less):			
—Share-based compensation expenses	**35,240**	27,773	26.9%
—Gain on disposal of subsidiaries	**(326,540)**	(98,155)	232.7%
—Gain on disposal of interests in equity-accounted investees	**(3,884)**	(16,729)	(76.8)%
—Net realized and unrealized loss on financial instruments carried at FVPL	**24,927**	17,249	44.5%
—Impairment losses of non-current assets	**107,250**	87,864	22.1%
—Interest expenses on preferred shares issued by subsidiaries	**24,446**	27,671	(11.7)%
Non-HKFRS adjusted net profit/(loss) for the year	**(100,134)**	(222,786)	Loss narrowed by 55.1%

Capital Management

The primary goal of the Group's capital management is to maintain the Group's stability and growth, ensure its normal operation and maximize shareholders' value. The Group reviews and manages its capital structure on a regular basis, and makes timely adjustments to it in light of changes in economic conditions. To maintain or realign the capital structure, the Group may raise capital by way of bank loans, issuance of equity or convertible bonds.

Liquidity and Financial Resources

As at 31 December 2025, the Group had US$682.5 million of cash and cash equivalents, as compared to US$713.0 million as at 31 December 2024. Such decrease was mainly attributable to (i) the Group's capitalised expenditure; (ii) the cash paid for the repayment of principal and interest on interest-bearing borrowings and for the distribution of dividends; and (iii) the repurchase of shares during the Reporting Period. The approach of the Board to managing liquidity of the Group is to ensure sufficient liquidity at any time to meet its matured liabilities in order to avoid any unacceptable losses or damage to the Group's reputation.

Borrowings and Liabilities to Assets Ratio

Total borrowings of the Group, including interest-bearing borrowings and convertible bonds, as at 31 December 2025 were US$1,549.3 million, representing a decrease of US$47.8 million as compared to US$1,597.1 million as at 31 December 2024. During the Reporting Period, the liabilities to assets ratio (calculated as total liabilities divided by total assets) of the Group decreased from 68.5% as at 31 December 2024 to 59.4% as at 31 December 2025.

Net Current Assets

The Group's net current assets as at 31 December 2025 were US$504.5 million, as compared to US$558.3 million as at 31 December 2024.

Foreign Exchange Exposure

The Group is exposed to currency risk primarily from sales, purchases, borrowing and lending which give rises to receivables and payables that are denominated in a foreign currency (mainly CNY, Euro and JPY). During the Reporting Period, the Group recorded a net exchange gain of US$8.4 million, as compared to a net foreign exchange loss of US$12.3 million for the year ended 31 December 2024. The Group did not have any significant hedging arrangements to manage foreign exchange risk but has been actively monitoring and overseeing its foreign exchange risk.

Capital Expenditure

Except for the above mentioned items, the Group's total capital expenditure during the Reporting Period amounted to approximately US$101.8 million, which was used for (i) construction of buildings; (ii) acquiring equipment and machinery; and (iii) expenditures for R&D projects in development stage.

Charge on Assets

As at 31 December 2025, for the purpose of securing bank loans with a carrying value of US$750.2 million, the Group had mortgaged its production buildings held for own use and land use right, and pledged the equity interest held by the Group in several subsidiaries and certain patents. In order to obtain the 2029 convertible loans, the Group pledged (i) a property situated in the US and (ii) shares held in certain subsidiaries.

FUTURE INVESTMENT PLANS AND EXPECTED FUNDING

Looking ahead, the Group will continue to expand its business in both domestic and overseas markets, explore its potential and improve the Group's financial health. Investment in working capital and capital expenditure will be supported by various sources of financing, including but not limited to cash flows generated from operating activities, bank borrowings and equity financing.

SCOPE OF WORK OF KPMG

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended 31 December 2025 as set out in the preliminary announcement have been agreed by the Group's auditor, KPMG, Certified Public Accountants, to the amounts set out in the Group's audited consolidated financial statements for the year. The work performed by KPMG in this respect did not constitute an assurance engagement and consequently no opinion or assurance conclusion has been expressed by KPMG on the preliminary announcement.

EXTRACT OF INDEPENDENT AUDITOR'S REPORT

The following is an extract of the independent auditor's report issued by the Group's independent auditor, KPMG, Certified Public Accountants of Hong Kong on the consolidated financial statements of the Group for the year ended 31 December 2025:

Opinion

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2025 and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with HKFRS Accounting Standards as issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

Material uncertainty related to going concern

We draw attention to note 1(b) to the consolidated financial statements, which indicates that as at 31 December 2025, the Group had (i) bank borrowings of US$414,387,000 due within 1 year, and (ii) convertible bonds issued by the Company of US$215,873,000 which are due for early redemption in December 2026. In addition, certain non-current bank borrowings and convertible bonds amounting to US$750,049,000 are subject to the fulfilment of covenants relating to certain of the Group's financial performance and ratios. For the year ended 31 December 2025, the Group's continuing operations incurred a net loss of US$255,713,000. These conditions, along with other matters as set forth in note 1(b) to the consolidated financial statements, indicate the existence of a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

The aforesaid "note 1(b) to the consolidated financial statements" in the extract from the independent auditor's report is disclosed as note 2 to the financial statements as set out in this announcement.

CORPORATE GOVERNANCE PRACTICES

The Company strives to maintain high standards of corporate governance to safeguard the interests of its shareholders and to enhance corporate value and accountability. Throughout the year ended 31 December 2025, the Company has complied with all the applicable code provisions (the "**Code Provisions**") as set out in the Corporate Governance Code (the "**CG Code**") (version up to 30 June 2025*) contained in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") with the exceptions as addressed below:

Pursuant to Code Provision C.2.1 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive officer should be clearly established and set out in writing. The Chairman and Chief Executive Officer of the Company are held by Dr. Zhaohua Chang ("**Dr. Chang**"). Dr. Chang has assumed the responsibility of the Executive Director and the Chairman of the Board and is responsible for managing the Board and Group's business. As the Board considers that Dr. Chang has in-depth knowledge of the Group's business and can make appropriate decisions promptly and efficiently, he also assumed the position of the chief executive officer of the Company. Nevertheless, the Board will continue to review the efficacy of the Group's corporate governance structure to assess whether the separation of the positions of chairman and chief executive officer of the Company is necessary.

Effective on 27 June 2025, Mr. Jonathan W Chen has been appointed as the Rotating Co-chief Executive Officer of the Company, subject to rotation on a yearly basis and adjustment based on his performance. The setup of the office of a rotating co-chief executive officer aims at, among others, further enhancing the Group's global corporate governance standards, comprehensively improving its international and professional operational capabilities, and substantively expanding the Group.

The Company will continue to review and enhance its corporate governance practices to ensure compliance with the CG Code.

* On 1 July 2025, the amendments to the CG Code came into effect and the requirements under the new CG Code will apply to corporate governance reports for financial years commencing on or after 1 July 2025.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules as its code of conduct regarding securities transactions by directors.

Specific enquiry has been made of all the directors of the Company (the "**Directors**") and the Directors have confirmed that they have complied with the Model Code for transactions in the Company's securities throughout the financial year ended 31 December 2025.

The Company has also established written guidelines on no less exacting terms than the Model Code (the "Employees Written Guidelines") for securities transactions by employees who are likely to be in possession of unpublished inside information of the Company.

No incident of non-compliance with the Employees Written Guidelines by the employees was noted by the Company.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the year ended 31 December 2025, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares). As at 31 December 2025, the Company did not hold any treasury shares.

SIGNIFICANT INVESTMENT HELD, MATERIAL ACQUISITION AND DISPOSAL OF SUBSIDIARIES AND ASSOCIATED COMPANIES

Save as disclosed in Note 15 to this announcement, there was no other significant investment or material acquisition and disposal of subsidiaries and associated companies by the Company during the year ended 31 December 2025.

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

The Directors are not aware of any significant event requiring disclosure that has taken place subsequent to 31 December 2025 and up to the date of this announcement.

PUBLIC FLOAT

From information publicly available to the Company and within the knowledge of the Directors, at least 25% of the Company's total issued share capital was held by the public at all times during the financial year ended 31 December 2025 as required under the Listing Rules.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Company's Articles of Association and the laws of the Cayman Islands, which would oblige the Company to offer new Shares on a pro-rata basis to the existing shareholders.

FINAL DIVIDEND

The Directors do not recommend the payment of a final dividend for the year ended 31 December 2025 (2024: nil).

AUDIT COMMITTEE

The Company has established the Audit Committee with written terms of reference in compliance with the CG Code. As at the date of this announcement, the Audit Committee comprises three members: Mr. Jonathan H. Chou (Chairman), Mr. Chunyang Shao and Dr. Qingbing Men. The Audit Committee has reviewed and discussed the annual results for the year ended 31 December 2025.

PUBLICATION OF RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This annual results announcement is published on the websites of Hong Kong Exchanges and Clearing Limited (http://www.hkexnews.hk) and the Company (http://www.microport.com). The 2025 annual report of the Company will be dispatched to shareholders (if requested) and will also be available at the websites above in due course.

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 31 March 2026

As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors of the Company are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*